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PREFACE 
 
In this work we studied the role of  hERG1 potassium channel and the luteinizing 
hormone receptor (LHR) in neoplastic and preneoplastic conditions. The present thesis 
is divided into three parts (three chapters). The first part concerns the depth study of 
hERG1 channel in Barrett‟s esophagus (BE) and its role during the progression to 
esophageal adenocarcinoma (EA), in order to (a) confirm hERG1 expression in a large 
cohort of BE patients (larger than the cohort studied in Lastraioli E et al 2006), (b) 
evaluate hERG1 expression during BE progression to esophageal dysplasia and EA. To 
deepen this topic and to better study the biology of hERG1 in BE, we developed three 
different mouse models of BE. Such models will be useful also to evaluatetherapeutic 
interventions and pharmacological tests. This study was also aimed at testing the 
possibility of considering hERG1 as a marker of BE progression to be further exploited 
for BE surveillance screening protocols. The second part of the present thesis was aimed 
at studying the effects of LH over-expression induction in the endometrium in vivo. For 
this purpose we generated a transgenic mouse model over-expressing hLHR in the 
reproductive tract with the aim of determining whether: (a) LH/hCG-R over-expression 
is capable of inducing the development of Endometrial Cancer (EC) per se. (b) LHR 
over-expression in endometrial cells is might be responsible of a more aggressive 
behaviour of differentiated EC cells. This model could be a useful model not only for 
deciphering the genetic basis of EC development, but also for developing and testing 
novel therapeutic options in preclinical studies. In the last part of the thesis we 
evaluated the expression levels of LHR and two ion channels, such as hERG1 and 
KCNA7, in a cohorts of EC patients, in order to search for associations between the 
expression of the two genes and a number of co-factors including clinical and 
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pathological parameters. We have chosen to study LHR because it is proven to be 
involved in EC invasion and metastatic spread. As concerning hERG1 it was chosen 
because it was previously found to be aberrantly expressed in a several human tumors, 
as endometrial cancer, among others. 
In addition, we also evaluated the mRNA levels of KCNA7 ion channel, supposed to be 
dysregulated in EC (Fortunato A., PhD thesis). 
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CHAPTER 1 
 
1. INTRODUCTION 
 
1.1 CLINICAL PRESENTATION OF BARRETT’S ESOPHAGUS (BE) 
The esophagus serves as a dynamic tube, pushing food toward the stomach, where 
digestion and absorption take place. Mucus produced by the esophageal mucosa 
provides lubrication and eases the passage of food. Active peristaltic contractions propel 
residual material from the esophagus into the stomach. During reflux, the esophagus 
also serves as a passageway for gastrointestinal (GI) contents traveling retrograde from 
the stomach. The wall of the esophagus consists of four layers: mucosa, submucosa, 
muscularis propria, and adventitia (Kuo B et al 2006). The mucosa is composed by: a 
nonkeratinized squamous epithelium; a lamina propria, a thin layer of connective 
tissue; a muscolaris mucosa, a thin layer of longitudinally, irregularly arranged smooth 
muscle fibers which separates the lamina propria from the submucosa. The submucosa 
contains connective tissue as well as lymphocytes, plasma cells, nerve cells, vascular 
network, and mucous glands. The esophageal glands are small racemose glands of 
mucous type and their secretion is important in esophageal clearance and tissue 
resistance to acid. The muscularis propria is responsible for motor function. The 
superior third is composed exclusively of voluntary striated muscle and the distal third 
is composed of smooth muscle. In between there is a mixture of both, called the 
transition zone. The adventitia is an external fibrous layer that covers the esophagus 
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composed of loose connective tissue and contains vessels, lymphatic channels, and 
nerve fibers (Kuo B et al 2006). Unlike other areas of the GI tract, the esophagus does 
not have a distinct serosal covering. This allows esophageal tumors to spread more 
easily and makes them harder to treat surgically. The missing serosal layer also makes 
luminal disruptions more challenging to repair. Originally the term “Barrett‟s 
esophagus” was used to describe an esophagus in which a portion of the normal 
squamous mucosa was replaced by columnar epithelium. Since the 1950s, when the 
term became popularized, much has been learned about this condition, and new 
concepts continue to emerge that force reevaluation of this disorder. Gastroesophageal 
reflux disease (GERD) is a prevalent entity in Western countries and Barrett's 
esophagus (BE) is one of its main complications (De Meester S R et al 200). BE is a 
pathologic condition easily detectable at endoscopy and characterized by the 
replacement of the squamous epithelium of the distal esophagus by a columnar-type 
mucosa (intestinal metaplasia) (Figure 1). 
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Figure 1: Normal esophagus versus Barrett‟s esophagus (A) Normal appearance of 
squamocolumnar junction at gastro-esophageal junction. (B) Normal esophageal squamous 
mucosa. (C) Tongues of Barrett‟s esophagus radiating orad from the gastro-esophageal 
junction. (D) Biopsy specimen of intestinal metaplasia (arrow points to goblet cell) 
(Shaheen NJ et al 2009). 
 
In BE patients, examination by upper endoscopy show cephalad displacement of the 
squamocolumnar junction. The length of the displaced squamocolumnar junction should 
be measured during endoscopy: longer than 3 cm is long-segment Barrett‟s esophagus; 
3 cm or shorter is short-segment Barrett‟s esophagus. Previously, investigators have 
suggested that short segments are not clinically significant, but other research has 
shown an increased cancer risk in even short-segment disease compared with the 
general population (Sharma P et al 1997; May A et al 2002). Therefore, the most 
common current definition of Barrett‟s oesophagus is salmon-coloured mucosa of any 
length in an oesophagus harbouring goblet cells. BE is precursor of esophageal 
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adenocarcinoma (EAC) and may progress to low-grade dysplasia (LGD), high-grade 
dysplasia (HGD) or adenocarcinoma (Shaheen NJ et al 2009). 
 
1.2 EPIDEMIOLOGY 
Barrett‟s esophagus is highly prevalent in the general population and especially in 
people with chronic reflux conditions, but in some patients the condition is 
asymptomatic. Decisions regarding endoscopic screening and understanding of the 
cancer risk partly depend on the prevalence of Barrett‟s esophagus in the general 
population. In a prospective study of a random patient sample, the prevalence of BE in 
the general population from Northern Europe who underwent upper endoscopy was 
1.6%, very similar to the estimates made by experts, based on frequency of reflux 
symptoms and the presence of BE in patients with heartburn (Ronkainen J et al 2005). 
In studies of simultaneous endoscopy in healthy patients undergoing screening 
colonoscopy for colorectal cancer, the prevalence ranged from 5,6% in a US 
Midwestern population, 25 to 15–25% in elderly people (Rex DK et al 2003; Ward EM 
et al 2006). It follows that the real prevalence of BE in living adults is difficult to 
ascertain, because individuals with Barrett‟s are often asymptomatic and do not seek 
care. Moreover, the true prevalence depends also on demographic features (sex, age, 
ethnicity) together with geographical variations. In 1990, the prevalence in Olmsted 
County (USA), was about 21-fold higher than the clinically recognized cases in the 
county, suggesting that many, if not most, patients with Barrett‟s esophagus remained 
unrecognized. More than 40% of the patients with Barrett‟s esophagus reported no 
reflux disease and the investigators were unable to consistently identify risk factors for 
Barrett‟s esophagus in asymptomatic patients. Although the prevalence in the general 
population is substantial, it is much higher in patients undergoing upper endoscopy to 
investigate chronic reflux symptoms, at 5–15% (Westhoff B et al 2005).  Zagari et al 
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analyzed 1033 patients originally identified as part of a large multicenter cross-sectional 
study on gallstone disease (Zagari RM et al, 2008). Of these patients, 1.3% (13) had 
histologically confirmed BE, while 0.2% (2) had long-segment BE. These estimates 
suggest that the prevalence of BE is between 0.5 – 2% of unselected individuals. In 
individuals with reflux symptoms, prevalence estimates are more variable, ranging from 
5–15% (Westhoff B et al 2005; Runge TM et al 2015). The majority of the studies 
suggest an annual risk of adenocarcinoma to be 0.4–1% in patients with BE, 
representing a 50 to 70-fold increase compared with the general population (Alcedo J et 
al 2009). The incidence, prevalence, and risk of neoplastic changes in BE are not well 
established in the European Mediterranean area. Diet and lifestyle in this geographic 
area differ from those in other Western countries, and the prevalence of GERD is lower 
than reported for US population. Moreover, some European data (excluding data from 
the UK) suggest that the incidence of BE and the risk of adenocarcinoma development 
are lower than that observed in the USA (Alcedo J et al 2009). 
 
1.3 RISK FACTORS FOR BE DEVELOPMENT 
GERD: Gastroesophageal reflux disease (GERD) is a central risk factor for BE 
development. Numerous case-control studies have shown that individuals with GERD 
are 6–8 times more likely to have BE (Anderson LA et al 2007). Longer duration of 
GERD may create an environment conducive to the development of BE (de Jonge PJ et 
al 2014). However, the presence of reflux symptoms is neither sensitive nor specific for 
pathologic acid reflux, and indeed symptom severity does not correlate well with BE 
risk (Avidan B et al 2002). In any case, longer duration of GERD symptoms predicts 
increased likelihood of BE (Conio M et al 2002). In summary, reflux is associated with 
GERD, but symptoms of reflux cannot distinguish those with increased acid reflux from 
those without. It is likely that a genetic predisposing to the development of BE 
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combined with prolonged acid exposure and mutagenic events, including oxidative 
stress, may act synergistically in patients who develop EAC (Runge TM et al 2015). 
Obesity: Obesity, measured by BMI and central adiposity, has been studied extensively 
as a risk factor for BE. The incidence of BE and EAC have risen dramatically in the past 
40–50 years in Western societies, concurrent with rapid increases in the rate of obesity. 
From 1976 to 1991, the prevalence of obesity at all ages rose from 25% to 33%, and it 
now approaches 35% in adults (Ogden CL et al 2014). Obesity can be assessed in 
several ways. High body mass indices and especially central adiposity have been shown 
to have a significant association with BE. A 2009 meta-analysis that included 11 
observational studies showed an increase in the risk of BE in patients with a BMI > 30 
kg/m2 compared to those with BMI < 30 kg/m2 (Kamat P et al 2009). Patients with BE 
have been shown to have higher BMIs than either general controls or individuals with 
GERD but not BE (Spechler SJ et al 2011). Because BMI does not take into account the 
distribution of body fat, the estimated risk increase in the obese may actually be poorly 
estimated by BMI measurements. In fact, more recent work has shown that central 
adiposity, rather than BMI, may be the true driver of increased BE risk (Edelstein ZR et 
al 2007). It is possible that the male predominance among EAC cases could be 
explained in part by the fact that overweight males distribute fat preferentially to their 
trunk, and this central adiposity drives the risk increase (Berger NA et al 2013). 
Alcohol: Alcohol use has been studied extensively as a possible risk factor for 
BE. Some work has suggested an inverse correlation between wine intake and BE risk 
(Thrift AP et al 2014). The most robust evidence we have on the issue comes out of the 
BEACON consortium, in which the data from 5 studies were pooled to assess risk of 
alcohol use (Kubo A et al 2009). Among 1,028 cases and 1,282 controls, alcohol use 
was stratified by gender and by number of drinks per day (Thrift AP et al 2014). There 
was a borderline significant inverse correlation between BE and any degree of alcohol 
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intake. Drinking 3 to <5 drinks per day was associated with a statistically significant 
reduction in BE risk, but with more or less alcohol consumed no statistically significant 
results were found. When assessing beverage-specific data, wine consumption was 
associated with an inverse risk of BE (Kubo A et al 2009). The preponderance of 
evidence supports no association between alcohol intake and BE risk. What was at one 
time thought to be a minor risk factor for BE now appears to confer no additional risk at 
all. Alcohol might indeed be protective, but in order to fully answer this question, more 
data are needed (Runge TM et al 2015). 
Cigarette smoking: The majority of studies have found an association between 
cigarette smoking and an increased risk of developing BE (Cook MB et al 
2014). However, there was significant heterogeneity between studies. To explore a 
possible synergistic effect between GERD and tobacco use in the genesis of BE, Cook 
et al. conducted modeling to assess the concurrent effects of smoking and GERD.
 
They 
found that the Odds Ratio (OR) of Barrett‟s increased significantly when both GERD 
and smoking were present, compared to when smokers did not have GERD (Cook MB 
et al 2014). However, not all studies have identified smoking as a risk factor for BE. 
Thrift et al studied 258 patients with BE in a case-control study from Houston. These 
researchers found no association between smoking and BE in either group, even when 
stratified by pack-year exposures, length of time smoking, or number of cigarettes/day 
(Thrift AP et al 2014). 
Helicobacter pylori: H. pylori infection can cause gastritis that decreases gastric acid 
secretion, protecting the esophagus from acid reflux and its complications (Fischbach 
LA et al 2012).  H.pylori is also known to have a strong association with intestinal 
metaplasia in the body and antrum of the stomach (Stemmermann GN 1994). Temporal 
associations have been made between the decreasing prevalence of Hp infection in 
developed countries and the increasing prevalence of EAC.
 
Corley et al showed that H. 
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pylori was inversely associated with BE in a case-control study design (el-Serag HB et 
al 1998; Corley DA et al 2008).  While the mechanisms underlying this inverse 
association are not fully understood, they may relate to decreased acid production in the 
setting of H. pylori infection (especially with associated atrophic gastritis) or via 
alterations in the microbiome (Runge TM et al 2015). 
 
1.4 PATHOGENESIS 
The development of Barrett‟s esophagus is likely a two-step process. The first step 
involves the transformation of normal esophageal squamous mucosa to a simple 
columnar epithelium called cardiac mucosa. This occurs in response to chronic injury 
produced by repetitive episodes of gastroesophageal refluxing of acid and bile that 
damage esophageal squamous cells. The change from squamous to cardiac mucosa 
occurs relatively quickly, within a few years, while the second step, the development of 
goblet cells indicative of intestinal metaplasia, proceeds slowly, probably over 5-10 
years (Oberg S et al 2012). Once present, Barrett‟s esophagus can progress to low- and 
high-grade dysplasia, and ultimately to adenocarcinoma. It is not known why the 
damage is repaired through columnar metaplasia rather than by regeneration of more 
squamouscells. Barrett metaplasia could result from transdifferentiation, in which 
squamous cells change into columnar cells through reflux-induced alterations in 
expression of key developmental transcription factors, or from transcommitment, in 
which esophageal stem cells (in the basal layer of the squamous epithelium or in the 
ducts of submucosal glands) that normally differentiate into squamous cells instead 
differentiate into columnar cells (Burke ZD et al 2012). Studies using mouse models has 
suggested that Barrett metaplasia might result from the proximal migration of stem cells 
from the gastric cardia or from expansion of a nest of residual embryonic cells at the 
gastroesophageal junction (Quante M et al 2012; Wang X et al 2011). The diagnosis of 
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Barrett‟s esophagus is suspected when an endoscopy reveals columnar mucosa in the 
esophagus and confirmed when biopsy specimens of that columnarmucosa show 
specialized intestinal metaplasia with its characteristic goblet cells. The distance 
between the gastroesophageal junction and the most proximal extent of Barrett 
metaplasia establishes whether there is long-segment (3 cm) or short-segment (<3cm) 
Barrett esophagus. 
 
1.5 PROGRESSION OF BE TO EAC 
The development of intestinal metaplasia within cardiac mucosa heralds the onset of a 
mucosal change that ultimately may lead to the development of esophageal 
adenocarcinoma. With continued inflammation and irritation of the metaplastic 
intestinal epithelium, some patients will progress through low-grade dysplasia, high-
grade dysplasia, and subsequently adenocarcinoma. It is unknown whether the 
movement toward cancer is due to mitogenesis secondary to chronic mucosal injury, or 
mutagenesis as a consequence of exposure to a mutagen. One theory is that bile salts in 
their unionized state act as mutagens. If bile salts are demonstrated to contribute to the 
development of malignancy, then early intervention with an antireflux procedure should 
be encouraged (De Meester S R et al 2000). The precise risk of developing 
adenocarcinoma in patients with Barrett‟s esophagus is unknown, however, it likely is 
0.2% to 2.1% per year for a patient without dysplasia, which is an incidence 30 to 125 
times that of the general population (Provenzale D et al 1994). Although intestinal 
metaplasia is itself a premalignant condition, the development of high-grade dysplasia is 
associated with a significantly increased risk for adenocarcinoma. Several reports have 
correlated the progression of dysplasia within Barrett‟s with other cellular and genomic 
alterations, including mutations of the tumor suppressor gene p53, aneuploidy, and loss 
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of the Y chromosome (Krishnadath KK et al 1995; Krishnadath KK et al 1995) (Figure 
2). 
 
 
Figure 2: Description of the progression from GERD to EAC. 
 
Importantly, any focus of intestinal metaplasia is capable of undergoing dysplastic 
change and ultimately becoming an invasive adenocarcinoma. Cameron and Carpenter 
have demonstrated that areas of dysplasia and cancer within long segments of intestinal 
metaplasia are often small and patchy, and that microscopic areas of different grades of 
dysplasia are often dispersed throughout the Barrett‟s. They suggested that dysplasia 
develops simultaneously in many areas and ultimately becomes confluent rather than 
spreading progressively outward from one site (Cameron AJ and Carpenter HA 1997). 
In addition, they noted that cancers developed throughout the length of the intestinal 
metaplasia, including distally near the stomach (Cameron AJ and Carpenter HA 1997). 
If intestinal metaplasia is present in a segment of columnar epithelium, it is always at 
the proximal end of the columnar segment. It may extend distally to involve most or all 
of the columnar segment, but it may be limited to the area near the squamocolumnar 
junction. Because available evidence suggests that adenocarcinoma occurs only within 
areas of intestinal metaplasia, it is likely that in these prior reports the intestinal 
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metaplasia was limited to the proximal portion of the columnar-lined distal esophagus 
(De Meester S R et al 2000). 
 
1.6 MARKERS FOR PROGRESSION FROM BE TO DYSPLASIA/CANCER 
Numerous studies have attempted to assess the utility of molecular biomarkers to 
predict progression and assist with risk stratification. If low risk patients can be 
accurately identified, then little or no follow-up may be warranted. Alternatively, 
chemopreventive or endoscopic interventions could be targeted to high-risk patients. 
However, to date none of the candidate biomarkers has been prospectively validated. 
P53 may have the most promise of any of the biomarkers for predicting neoplastic 
progression in patients with Barrett‟s. Kastelein et al studied the effect of aberrant p53 
expression in a case-control study and found that P53 overexpression was associated 
with significantly increased risk of progression to either high-grade-dysplasia (HGD) or 
EAC (Kastelein F et al 2013). Among those with loss of p53 expression, the risk of 
progression was even higher. Low–grade-dysplasia (LGD) alone was far less predictive 
of progression and the positive predictive value of progression was 15% with LGD 
alone compared to 33% in patients with both LGD and aberrant p53 expression 
(Kastelein F et al 2013). Bird-Lieberman et al performed a retrospective, case-control 
study from a large cohort of patients in Northern Ireland. In that study, low-grade 
dysplasia, abnormal DNA ploidy, and Aspergillus oryzae lectin (AOL) were all risk 
factors for progression. LGD contributed significantly, but AOL and ploidy were also 
independent predictors of advancement to EAC (Bird-Lieberman EL et al 2012). A 
prospective study by Davelaar et al tested a protocol comparing p53 staining by 
immunohistochemistry and fluorescence in situ hybridization (FISH) to test on cytology 
specimens. They found that p53 abnormalities detected by immunohistochemistry and 
FISH were both independent predictors of progression (Davelaar AL et al 2015). In 
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addition, when both p53 and FISH were used, detection of LGD, HGD, and EAC was 
100% accurate, both p53 and FISH improved the risk stratification capability of p53 
alone. 
Despite the significant advances in biomarker development, significant barriers remain. 
Of all the biomarkers currently identified, the greatest potential for clinical application 
may lie with assays using p53. P53 can be easily tested, and in multiple studies has been 
documented to improve the reproducibility of the diagnosis of dysplasia and to predict 
neoplastic progression (Timmer MR et al 2013). Due to the imperfect nature of 
dysplasia alone as a predictor of neoplastic progressions, work on molecular biomarkers 
continues. To date, however, no biomarkers are approved for diagnosis or risk 
stratification. Recent British Society of Gastroenterology guidelines propose that p53 
immunostaining should be considered, in addition to routine clinical diagnosis, for BE 
diagnosis (Fitzgerald RC et al 2014). However, Pathology societies have yet to develop 
guidelines for the interpretation and reporting of p53 staining by IHC in Barrett‟s 
esophagus (Runge TM et al 2015). 
 
1.7 ION CHANNELS IN CANCER 
Ion channels are pore-forming transmembrane proteins that regulate passive ion fluxes 
that are important for key cell processes. They are good potential markers because of 
their localization at the plasma membrane level. Ion channels are  progressively 
emerging as a novel class of membrane proteins aberrantly expressed in several types of 
human cancers. Besides regulating different aspect of cancer cell behavior, ion channels 
can now represent novel cancer biomarkers (Lastraioli E et al 2015). It is known that 
proliferating cells tend to be more depolarized than nonproliferating cells. As the cell 
cycle progresses, membrane potential fluctuates such that cells become relatively 
hyperpolarized just before the G1 to S transition, as K
+
 channels allow K+ to flow out of 
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the cell. Cells tend to depolarize as G2 transitions to M phase (Blackiston DJ et al. 
2009, Boonstra J et al. 1981). Conduction through ion channels can regulate cellular 
proliferation in normal development of cells in mammals. For example, the expression 
of voltage-gated Kv1.3 (KCNA3) and Kv1.5 (KCNA5) subunits increases as cells 
progress from G0 to G1 in the cell cycle, causing a transitory increase in K
+
 current 
during G1 in rodent glial progenitor cells. Inhibition of these channels arrest 
oligodendrocytes in G1 (Chittajallu R et al. 2002). Inhibition of delayed outward 
rectifying K
+
 currents also can arrest glial precursor cells in G1, suggesting that the K
+
 
current regulates progression from G1 to S, at least in a normal developmental context 
in the brain (MacFarlane SN & Sontheimer H 2000). In the context of cancer, inhibition 
of voltage-gated K
+
 channels slows the proliferation of cancer cells (Chang KW et al. 
2003; Fraser SP et al. 2000; Menendez ST et al. 2010). Increased K
+
 current promotes 
proliferation. In human breast carcinoma cells, increased expression of Kv1.1 (KCNA1) 
promotes proliferation, and inhibition of K
+
 current slows proliferation (Ouadid-
Ahidouch H et al. 2000). K
+
 current, through KCNMA1, a KCa channel, also promotes 
the proliferation of breast cancer tumor cells, suggesting that the K
+
 current rather than 
the specific type of channel is important for proliferation (Oeggerli M et al. 2012). 
Moreover, increased activity of voltage-gated K
+
 channels promotes proliferation of 
colon cancer cells and malignant lymphocytes as well (Wang YF et al. 1992). Thus, in 
multiple cell types, different types of K
+
 channels promote cell cycle progression from 
G1 to S, and inhibition of K
+
 current can cause cell cycle arrest in G1. Recently, it was 
demonstrated that hyperpolarizing Cl
−
 channels promote cell cycle progression. For 
example, inhibition of volume-regulated Cl
−
 channels (VRCCs) causes p27 
accumulation and G1 cell cycle arrest in human embryonic kidney (HEK) cells, small 
cell lung cancer cells, and T-cell leukemia cells (Renaudo A et al. 2007). Furthermore, 
inhibition of Cl
−
 intracellular channel-1 (CLIC1) in human glioblastoma cells induces 
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G1 arrest, suggesting that hyperpolarizing currents consisting of both K
+
 and Cl
−
 are 
required for the G1 to S transition (Gritti M et al. 2014).  
One hypothesis about how do mechanically ion channels effect proliferation is that ion 
channel activity activates a signaling cascade, eventually modifying molecular cell 
cycle proteins. A second hypothesis is that ion channels regulate cell volume and 
therefore the concentration of cell cycle regulatory proteins that directly affect cell cycle 
progression (Rouzaire-Dubois et al. 2000; Bates E 2014). Ion channels are involved also 
in cancer cells migration. Many Na
+
 channel subunits are over-expressed in breast 
cancer cells, and increased expression correlates with increased metastasis (Chioni AM 
et al 2009). For example, the Nav1.5 α-subunit of a voltage-gated Na + channel is 
overexpressed in breast cancer cell lines that are highly metastatic, and phenytoin (an 
antagonist of this type of channel) inhibitsmetastatic properties (Yang M et al 2012). In 
general, data suggest that ion channels are involved not only in cancer proliferation but 
also in cell invasion and migration into neighboring tissue (Bates E 2014). 
 
1.8 hERG1 CHANNEL 
The human ether-a-go-go related gene (hERG) encodes the pore-forming subunit of a 
delayed rectifier voltage gated K
+
 (VGK) channel. These channels are variously referred 
to as IKr, hERG, or Kv11.1 (Gutman GA etal 2003). Commonly, KCNH2 is used when 
referring to the gene and hERG when referring to the channel protein, also known as 
Kv11.1. Within the family of ether-a-go-go related, there are three members, Kv11.1 
(hERG1), Kv11.2 (hERG2), and Kv11.3 (hERG3). KCNH2 was first cloned in 1994, by 
Warmke and Ganetzky, by screening a human hippocampal cDNA library with a mouse 
homolog of the Drosophila “ether-à-go-go” (EAG) K+ channel gene 
(Warmke JW, Ganetzky B 1994). The main biological function of hERG1 channel is to 
determine the rapid component of the delayed rectifier potassium current (IKr) which 
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regulates the repolarisation of the cardiac action potential. Mutations in KCNH2 gene 
are the basis of chromosome 7-associated long QT syndrome (LQTS), an inherited 
disorder associated with a markedly increased risk of ventricular arrhythmias and 
sudden cardiac death (Curran ME et al 1995). 
 
1.8.1 hERG1 Structure 
KCNH2 gene is localized on chromosome 7, in q35-36 position, and the coding region 
comprises 16 exons spanning approximately 33 kb of genomic sequence. The major 
transcript of KCNH2 (hERG1a) contains 15 exons and the protein is composed of 1159 
amino acids with a molecular mass of 127 kDa (Itoh T et al 1998;. Vandenberg JI et al 
2012). hERG1 channel is formed by coassembly of four identical α-subunits arranged 
symmetrically around a central pore, with each subunit containing six α-helical 
transmembrane segments (S1-S6): S1-S4 segments constitute the voltage sensor domain 
(VSD) and S5-S6 along with the intervening pore loop (S5-P-loop-S6) contributing to 
form the K
+
-selective pore. Both amino- and carboxy-terminals are located in the 
cytoplasm (Warmke JW, Ganetzky B 1994) (Figure 3). The functional channel is a 
tetramer with the pore domain from each of the four subunits lining the central ion 
conduction pathway.  
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Figure 3: Structure of a single hERG containing six α-helical transmembrane domains: S1-S6. 
PAS: PAS (acronym of Per Arnt Sim) domain; cNBD (cyclic nucleotide binding domain) 
(Sanguinetti MC et al 2006). 
 
Like other voltage-gated K
+
 channels, hERG1 channel contains multiple positive 
charges in the S4 domain, because it is reach in basic amino acids (4 arginine and 2 
lysines), and this acts as the primary voltage sensor for channel opening (Zhang M et al 
2004). Mutagenesis of S4 identified Arginine 531 as the most important positively 
charged residue for proper voltage sensing in hERG (Subbiah, RN et al 2005). 
Positively charged amino acids in S4 domain and negatively charged acidic residues 
(Asp residues) in S1-S3 can form transient salt bridge during the gating (Sanguinetti 
MC et al 2006). S5-P-loop-S6 of each subunit contribute to shape the pore of the 
channel and to determine potassium selectivity. The extracellular end of the pore is a 
narrow cylinder called the K
+
-selectivity filter that is optimally constructed for 
conduction of K
+
 ions (Sanguinetti MC et al 2006). The channel pore is asymmetrical 
and its dimensions change when the channel gates from a closed to an open state. Below 
the selectivity filter, the pore widens into a water-filled region, called the central cavity, 
that is lined by the S6 α-helices. In the large P loop there are 2 consensus site for N-
glycosylation, which is important for the proper anchorage of hERG protein at the 
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plasma membrane (Gong Q et al 2002). In addition to the membrane-spanning region, 
the hERG protein contains large cytoplasmic NH2-terminal and COOH-terminal 
domains. The NH2 terminus contains a Per-Arnt-Sim (PAS) domain that defines 
the ether-a-go-go subfamily of VGK channels (Warmke JW, Ganetzky B 1994). The 
COOH terminus contains a cyclic nucleotide binding domain (cNBD), which shares 
homology with the cNBD of CNG channels and hyperpolarization activated channels 
(HCN). hERG1 channels can exist in closed, open, or inactivated states (Figure 4). In 
the closed state, at negative voltage, the four S6 domains criss-cross near the 
cytoplasmic interface to form a narrow aperture that is too small to permit entry of ions 
from the cytoplasm (Doyle DA et al 1998). In response to membrane depolarization, the 
S6 α-helices splay outwards and increase the diameter of the aperture to allow passage 
of ions. Membrane depolarization slowly activates the channels, which then inactivate 
rapidly, especially at higher potentials. The kinetic of inactivation of hERG1 channels 
of is much more rapid than the kinetic of activation and the inactivation process is 
voltage-dependent (Vandenberg JI et al 2012). 
 
Figure 4: hERG channels are either closed, open or inactivated, depending on transmembrane 
voltage (Taken from MC Sanguinetti et al 2006). 
 
1.9 ION CHANNELS AND ESOPHAGEAL ADENOCARCINOMA (EAC) 
From a histopathological point of view, two types of cancer are the most frequent: 
squamous-cell carcinoma (ESCC) and adenocarcinoma (EAC). Barrett's Esophagus 
(BE) represents a precursor lesion for EAC. Although BE progression towards true 
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invasive cancer is not frequent, it represents a serious clinical problem, requesting 
frequent patients' endoscopic surveillance. Among voltage-gated K
+
 channels (VGKC), 
completely different patterns of expression were found between two members of the 
KCNH family: Kv10.1 (KCNH1) was expressed in ESCC compared with the 
corresponding normal tissue, the protein was associated with depth of invasion and was 
an independent negative prognostic factor (Ding XW et al 2008). On the contrary, 
Kv11.1 (KCNH2) potassium channels were shown to be expressed in precancerous 
lesions (BE, dysplasia) as well as in EAC (Lastraioli E et al 2006). It was also 
demonstrated that the Kv11.1 (KCNH2) channel is significantly associated with 
malignant progression towards EA. Kv11.1 (KCNH2) channels are also overexpressed 
in ESCC samples, but no statistically significant correlations emerged with 
clinicopathological characteristics. Nevertheless, Kv11.1 (KCNH2) expression 
negatively affects patients' survival (Ding XW et al 2008). Other channel types are 
expressed and functional in esophageal cancer cells. For example, TRPC6 is 
overexpressed in ESCC with respect to normal esophageal tissue at both protein and 
mRNA levels (Shi Y et al 2009). A recent report evidenced correlations of TRPC6 with 
T and staging and an association between TRPC6 mRNA and poor prognosis (Zhang SS 
et al 2013; Lastraioli E et al 2015). 
 
1.10 hERG1 CHANNEL IN CANCER 
In recent years, hERG1 channels has been detected in several types of human cancers 
and was found involved in many aspect of tumor progression: enhanced cell 
proliferation, angiogenesis, cell survival, invasiveness and metastasis (Bianchi L et al 
1998, Arcangeli A et al 2009). hERG1 channels are overexpressed in human solid 
cancers of different histogenesis such as endometrial, colorectal, esophageal, pancreatic 
adenocarcinomas, as well as ovarian and brain cancers (Cherubini A et al 2000; 
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Lastraioli E et al 2004; Lastraioli E et al 2006; Feng J et al 2014; Asher V et al 2010; 
Masi A et al 2005). Data gathered in the last 15 years underlined that hERG1 channels 
are also important modulators of apoptosis and cell proliferation in leukemias and 
neuroblastomas (Wang H et al 2002; Pillozzi S et al 2002; Crociani O et al 2003). 
hERG1 channel can be considered a marker for malignant transition and its expression 
usually correlates to poor prognosis (Arcangeli A et al 2013; Lastraioli E et al 2012; 
Lastraioli E et al 2004). In this thesis we focused mainly on two types of solid cancer: 
esophageal cancer, which derives from Barrett‟s esophagus, and endometrial cancer. 
hERG1 in esophageal cancer: As mentioned above, two types of esophageal cancer are 
the most frequent: esophageal squamous-cell carcinoma and esophageal 
adenocarcinoma. KCNH2 gene and hERG1 protein were found to be expressed in a 
high percentage of esophageal squamous-cell carcinoma samples but no correlations 
emerged with clinicopathological features. Survival rates of hERG1-positive patients 
were shorter than hERG1-negative patients (Ding XW et al 2008). In 2006, Lastraioli et 
al. showed that hERG1 is overexpressed in the majority of BE samples (69%) while it 
absent in normal esophageal mucosa as well as samples taken from patients affected by 
esophagitis. It was also shown that hERG1 expression is switched on at early stages of 
BE cancerogenesis and it is also highly expressed in dysplasias and BE-derived 
adenocarcinomas, thus characterizing both early and late steps of esophageal 
cancerogenesis (Lastraioli E et al 2006). hERG1 channel expression also shows a 
significant association with malignant progression towards adenocarcinoma, since 89% 
of BE patients who developed EA were positive for hERG1 protein expression 
(Lastraioli E et al 2006).                                             
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2. MATERIALS AND METHODS 
 
2.1 Patients and tissue specimens 
Tissue samples were retrospectively obtained from different institutions belonging to 
GIRCG (Department of Clinical and Experimental Medicine, University of Florence; 
Pathology Division, Azienda Ospedaliero-Universitaria Senese; Pathology Division, 
Borgo Trento Hospital, Verona; Pathology Division, Morgagni-Pierantoni Hospital, 
Forlì; Pathology Division, Esine Hospital, ASL Vallecamonica Sebino; Insitute of 
Pathology, Spedali Civili, Brescia). A total of 125 BE, 16 ED and 25 EA paraffin-
embedded samples were collected.  
Diagnosis and histological grading were assessed in all cases using standard criteria by 
experienced pathologists (LM, CV, AT, LS, MC and VV). 
 
2.2 Immunohistochemistry 
Immunohistochemistry was performed as previously reported using an anti-hERG1 
monoclonal antibody directed against the S5-pore region (Dival Toscana Srl) at 1:200 
dilution and slides were incubated overnight at 4°C. Immunostaining was performed 
with a commercially available kit (PicTure Max kit and DAB, Invitrogen). 
 
2.3 Scoring assessment 
Samples were evaluated applying a scoring system frequently used for cytoplasmic and 
membrane proteins. Such scoring system combines the estimate of the percentage of 
positive cells with the staining intensity. Staining intensity was rated on a scale of 0–3, 
with 0 = negative; 1 = weak; 2= moderate, and 3= strong. The raw data were converted 
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to the combined score by multiplying the percentage and staining intensity values, 
obtaining a value between 0 and 300 for each sample. Only samples with a complete 
score equal to 0 were considered negative. 
 
2.4 Retrospective Case-Control Study 
A case-control study design has been chosen because the study addresses the potential 
association between a rare medical condition (EA in BE) and a relatively common 
marker (hERG1 expression). Cases are defined as BE subjects whose lesions progressed 
towards dysplasia/adenocarcinoma while Controls are BE patients, with at least a 
follow-up visit completed during the last 10 years, whose lesions didn‟t progressed at 
the last time when they were examined. Since there may be a considerable lag time 
between the diagnosis of BE and the progression towards EA, the date of BE diagnosis 
is defined as index date. Three controls will be individually matched per case for age at 
the index date and gender. Controls will be randomly chosen, without replacement, 
between all individuals with a follow-up duration equal to or longer than the interval 
between index date and EA diagnosis in the corresponding case. 
The number of samples collected reached a case-control ratio equal to 1:3 (26 
progressed BE and 78 not-progressed BE). The study population was therefore 
represented by 104 patients with complete follow up information. We calculated that, 
for a two-sided alpha error equal to 5%, with 15 cases available, a case-control ratio 
equal to 1:3, and a prevalence of hERG1 expression between controls equal to 10%, the 
study will have a power of 80% against a minimal detectable risk (odds ratio) of 6.7. 
According to our previous data, such a strong association should be plausible. 
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2.5 Statistical analysis 
Standard univariate and multivariate logistic regression analyses were performed to 
assure that the risk estimates for progression towards EA are appropriately adjusted for 
confounding and effect modification.  
Data were collected locally and thereafter transferred to the Clinical Trials Coordinating 
Centre (CTCC) of the Istituto Toscano Tumori, according to clear time lines and 
defined responsibilities. Incoming data will be checked in the CTCC for quality and 
comprehensiveness by a quality assurance system and queries will be done to the study 
center if there is as doubt about the validity of the data or if there are missing data. 
Statistical analysis were performed in collaboration of Dott. L.Boni (University of 
Florence). 
 
2.6 BE induction in mice 
13 Balb-C, 39 CD-1 mice (2-4 months of age, weighing 24-29g) and 33 FVB hERG1 
transgenic mice (2-4 months of age, weighing 23-30g), overexpressing hERG1 in GI 
tract [13], were operated to perform gastro-jejunal anastomosis (EJA), inducing gastro 
duodenal mixed reflux. Anesthesia was performed by an intraperitoneal injection of 
Avertin 2.5% (16μg/g body weight). A total of 85 mice were operated and only 15 of 
them survived after surgery: 6 CD-1, 5 Balb-C and 4 FVB hERG1 TG mice. We 
hypothesized that the high early mortality might be related both to hypothermia (caused 
by the heat loss from the abdomen) and anesthesia.  
Surgery was performed by placing the mouse on a small surgical table and, after a 2-3 
cm median incision of the skin and peritoneum, the esophagogastric junction was 
exposed. Distal esophagus was sectioned after clamping in order to prevent esophageal 
retraction and the gastric side stitched, at cardiac level, with suture thread Goretex 8/0. 
A small hole was performed in the jejunum wall by a 14 Fr intravenous cannula and 
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then the esophagus-jejunal anastomosis with silk 7/0 was performed. After successful 
repositioning of the viscera the abdominal wall was closed with nylon 4/0. A 
representative picture showing the result of the surgical procedure is reported in Fig 2A. 
Mice were sacrificed after 9 and 12 months. Furthermore, another set of experiment was 
performed using a mixed chemical-transgenic model of BE treating 10 3-month-old  IL-
1β TG mice with 0.2% deoxycholic acid (DCA) in the drinking water (pH 7.0). 7-8 
months after the beginning of the DCA-treatment mice were sacrificed. 
 
2.7 Histological and immunohistochemical analysis 
After the animal sacrifice the stomach and esophagus were removed and fixed in 4% 
formalin for 24 hours. Thereafter, samples were processed for paraffin embedding and 7 
µm longitudinal cut sections were obtained through a microtome and put on positive-
charged slides. 
Samples were stained with Hematoxylin/Eosin and Alcian Blue standardized protocols 
to detect goblet cells and then observed under a light microscope. 
Moreover, samples were stained with anti-hERG1 polyclonal antibody, in order to 
evaluate the expression of hERG1 channel. The antibody was diluted in UltraVBlock 
(LabVision) in PBS1:10 (v/v) at a final dilution 1:200. 
 
2.8 TG mouse models 
In this work we used two different transgenic mouse models. The first one was hERG1-
transgenic (TG) mouse model, which over-express hERG1 in the mucosa of the large 
intestine. This model was developed by our laboratory and was described in Fiore A 
2008 (Fiore A. et al 2013). Briefly, the hERG1 cDNA, tagged with the myc epitope and 
a poly-histidine (His) flag at the protein C-terminal, was put under the control of the 
human b-actin minimal promoter, with an intercalated floxed reporter EGFP gene, 
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which should block transgene transcription. The floxed EGFP gene was used to 
conditionally express hERG1 in gastro-intestinal tract. Unfortunately, because of 
transcriptional readthrough phenomenon TG mice expressed hERG1 both in the colon 
and in the liver even in absence of Cre-mediated recombination. Therefore, mice, due to 
the transcriptional control exerted by the b-actin promoter, can be considered to over-
express the hERG1 transcript ubiquitously. 
The second model was IL-1β transgenic (TG) mouse model. IL-1β transgenic mice were 
generated by targeting expression of hIL-1β to the esophagus using the Epstein Barr 
virus promoter (ED-L2) that targets the oral cavity, esophagus and squamous 
forestomach. This model was widely described in Quante M  2008 (Quante M et al 
2008).
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3. AIMS OF THE STUDY 
 
The present study was designed with the aims of: investigating hERG1 channel 
expression in a large cohort of BE patients using a monoclonal antibody anti-hERG1; 
determining the expression of hERG1 during BE progression toward esophageal 
adenocarcinoma. In this study we tested also the possibility of considering hERG1 as a 
progression marker in BE. In order to better study the biology of BE at the onset of the 
disease we developed three different BE mouse models: (a) a surgical model, obtained 
by esophagojejunal anasthomosis (EJA); (b) a mixed chemical-transgenic model, 
treating IL-1β TG mice with deoxycholic acid; (c) a mixed surgical-transgenic model, in 
which EJA was applied in a hERG1 TG mouse model. 
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1. RESULTS 
 
4.1 hERG1 expression in BE and during esophageal tumor progression. 
We previously showed that hERG1 expression was up-regulated in BE samples, 
compared to both normal esophageal mucosa and GERD samples without or with 
esophagitis (Lastraioli E et al 2006). In the present work we validated our previous data 
in a larger cohort of BE samples (125 patients), using an anti-hERG1 monoclonal 
antibody (Mab-hERG1, Dival Toscana Srl; Sesto Fiorentino, Italy) instead of the anti 
hERG1 polyclonal antibody previously used. The Mab-hERG1 was previously proven 
to give a clearer signal and hence easiness of interpretation. This antibody recognizes an 
extra-cellular epitope of hERG1 protein and for this reason can be used without 
permeabilization. No hERG1 expression was detected either in normal squamous 
epithelium (Figure 1A) or in areas displaying signs of esophagitis (Figure 1B). Instead, 
the expression of hERG1 can be clearly observed in metaplastic cells composing BE 
tissue (Figure 1C), but not all BE samples are hERG1 positive (Figure 1 D).  
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Figure 1: hERG1 expression in human esophageal carcinogenesis. IHC was performed as 
described in Materials and Methods with anti-hERG1 monoclonal antibody. A) Normal 
esophagus. B) Esophagitis. C) Representative BE sample expressing the hERG1 protein. D) 
Representative BE sample negative for hERG1 expression. Original magnification 20x. Scale 
bar: 100nm. 
 
These results not only confirm what previously published by Lastraioli et al (Lastraioli 
E et al 2006), but also show the lower background, with easiness of interpretation of the 
Mab-hERG1 labelling. Overall, hERG1 was expressed in 48% (60/125) BE samples 
(see also the bar graph in Figure 2A). We than defined a scoring system, taking into 
account both the percentage of labelled cells and the staining intensity. The score was 
obtained by multiplying the two values and was therefore ranging from 0 (negative) to 
300. Considering only positive samples (with scores >1), it emerged that BE samples 
have a median score equal to 145 ±86.03 (n=60).  
We also have collected and analyzed sixteen ED and twenty-five EA cases and hERG1 
expression was evaluated. Overall, hERG1 was expressed in 14 out of 16 (87,5%) ED 
and in 24 out of 25 (96%) EA (Figure 2A). When the positive samples were scored 
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according to the scoring system described above, BE samples showed a significantly 
lower median score (145 ±86.0), compared to ED (255 ±70.7, BE vs ED p=0.023) and 
EA (270±48.4, BE vs EA p<0.001) (Figure 2B).  
 
Figure 2: A) Histogram summarizing hERG1 expression in the three different groups of 
samples analyzed (BE, ED and EA). White bars: hERG1 negative samples, Black bars: hERG1-
positive samples. B) Histogram summarizing hERG1 scoring in the different groups (BE, ED 
and EA). Samples were scored as described in Materials and Methods. Analysis performed 
using 2-sided Student‟s T test revealed statistically significant differences between BE and ED 
(p=0.013), between BE and EA (p<0.001) and between ED and EA (p=0.007). White bars: BE; 
Grey bars: ED; Black bars: EA. 
 
Five cases, for which the entire progression from BE to ED and then EA was available, 
were fully analyzed and scored. Representative samples of BE, ED and EA are shown in 
Figure 3A-C. 
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Figure 3: hERG1 expression increase during EC progression to EA. A) BE sample. B) 
Esophageal Dysplasia (ED). C) Esophageal Adenocarcinoma (EA). Original magnification 20x.  
 
We evaluated hERG1 expression in BE, ED and EA of all the five cases and we 
analyzed the scorings: hERG1 positive BE samples showed a trend to increase hERG1 
expression during progression (Figure 4). 
 
 
Figure 4: Histogram summarizing hERG1 scoring in the different samples (BE, ED and EA) of 
5 representative patients. White bars: BE; Grey bars: ED; Black bars: EA. 
 
Collectively, these data allowed us to conclude that hERG1 is expressed in 
approximately half of BE samples, and its expression increases during BE progression 
to adenocarcinoma.  
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4.1 Case-control study. 
Subsequently, we investigated whether hERG1 might represent a biomarker of tumor 
progression in BE.  To this purpose we tested whether hERG1 was differentially 
expressed in progressed and not-progressed BE sample. We analized 104 BE primary 
samples with a follow-up of at least 10 years, provided from different institutions in 
Italy (GIRCG network). Accordingly, samples were divided in two groups: samples that 
progressed towards ED and/or EA in the follow-up time (pBE) and samples belonging 
to patients whose lesions did not progress to EA (npBE). The ratio between cases (pBE) 
and controls (pBE) was 1:3. For the case-control study samples were scored only as 
“positive” and “negative” for hERG1 expression. Representative examples of a npBE 
sample, which does not express the hERG1 protein, and of a pBE sample, which is 
positive for hERG1 expression are shown in figure 5A and 5B, respectively.  
 
 
Figure 5: hERG1 expression along tumor progression. A) Non-progressed BE. The 
representative sample here reported is negative for hERG1 expression. B) Progressed BE. A 
representative hERG1-positive sample is shown. Original magnification 20x. Scale bar: 100nm.  
 
Overall, hERG1 channel was expressed in 73,1% of pBE (19 out of 26) while only 
42.3% (33 out of 78) npBE expressed hERG1 (Figure 6). 
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Figure 6: Histogram showing hERG1 expression in progressed (pBE) and non-progressed BE 
(npBE). White bars: hERG1 negative; Black bars: hERG1 positive. 
 
Statistical analysis indicated a statistically significant association between hERG1 
expression in BE and the risk of progression to EA (Odds ratio= 3.70, 95% CI 
(Confidence Interval): 1.40-9.82; P=0.006) (Table 1).  
 
  
npBE (%) 
 
pBE (%) 
 
Odds Ratio 
 
95% CI 
P value 
(likelihood 
ratio test) 
hERG- 45 (57,7%) 7 (26,9%)  
3,70 
 
1,40-9,82 
 
P=0,006 hERG+ 33 (42,3%) 19 (73,1%) 
 
Table 1- Statistical analysis for the case-control retrospective study. npBE: not progressed BE, 
pBE: progressed BE. 
 
4.3 hERG1 expression in BE lesions of BE mouse models 
To better investigate the role of hERG1 channel in BE progression to EA, we also 
developed different BE mouse models, in which BE lesions were induced either 
surgically or chemically. The surgical model consisted in mice in which an esophago-
jejunal anastomosis (EJA) was performed (Figure 7A,B,C). For this purpose we used 
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either CD1 or Balb-C mice. Mice were sacrificed 9 to 12 months after surgery, and 
esophagus, stomach (atrophic) and intestine were removed to be analyzed for the 
detection of BE lesions through hematoxylin and eosin as well as Alcian blue staining 
(Figure 7D). All the operated animals showed the signs of gastric mucosal atrophy due 
to the EJA (Figure 7B,C). 4 out of 11 (36%) operated animals developed histologically 
detectable intestinal metaplasia in the lower esophagus, indicative of BE (Figure 7E, red 
arrow). One mouse also showed signs of ED in an area surrounding a BE lesion (Figure 
7E, yellow arrow).  
 
 
Figure 7: A) Drawing of the EJA performed in this study; B) representative specimen from an 
operated animal, showing EJA; C) EJA at the moment of the sacrifice: the yellow arrow 
indicates the esophagus, the white one indicates the atrophic stomach. D) Alcian Blue staining 
performed on Balb-C mice in order to detect goblet cells; E) IHC performed on Balb-C mice, in 
order to evaluate hERG1 expression, indicates that hERG1 is not expressed in normal 
esophageal tissue while it is up-regulated in metaplasia (red arrow) and dysplasia (yellow 
arrow). Original magnification 20x. 
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The second was a model of chronic esophageal inflammation: IL-1β transgenic mice 
received, in drinking water, 0.2% deoxycholic acid (DCA) for 7 months of treatment (as 
described in Materials and Methods) (Figure 8A). For this reason this model was a 
mixed “chemical-transgenic” model. Four out of 10 (40%) IL-1β TG DCA-treated mice 
developed histologically detectable BE lesions (Figure 8B). 
 
 
Figure 8: A) From left to right: birth and screening of IL-1β TG mice F1 generations 
(chemical-transgenic model of BE): each founder mouse is bred with a Wild Type partner. The 
IL-β TG mice are treated with 0,2% DCA for 7 months and then sacrificed. Alcian Blue (B) and 
IHC (C) staining performed on IL-1β TG mice DCA-treated in order to detect BE lesions and to 
evaluate hERG1 expression. Original magnification 20x. 
 
An IHC analysis was performed to evaluate the expression of hERG1 in BE lesions of 
either mouse models. It emerged that hERG1 was absent in normal tissue and in 
esophagitis in both types of models, while it is up-regulated in BE lesions of both 
mouse models (Figure 7E, Figure 8C, and Figure 9A) (mean score=130±28.7 in the 
surgical model and mean score = 113 ±37 in the chemical-transgenic model) as well as 
in the dysplasia observed only in the surgical model (mean score=270) (Figure 9B).  
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Figure 9: Datail of metaplastic (A) area and dysplastic area (B) of a Balb-C mouse sample. 
Original magnifications, 40x.  
 
Finally, we investigated whether BE lesions induced by the EJA surgical procedure 
occurred at higher frequency in mice over-expressing hERG1, we operated FVB hERG1 
transgenic (TG) mice whose hERG1 over-expression in the GI tract was proven in
 
Fiore 
A. 2013 (Fiore A. et al 2013). This model was a mixed “surgical-transgenic” model. 
Alcian Blue staining was also performed to detect intestinal metaplasia (Fig 10A), as 
above. Four out of 4 (100%) FVB hERG1 TG mice developed BE lesions 9-12 months 
after surgery (Fig 10B). 
 
 
 
Figure 10: A) Alcian Blue staining shows BE lesion in hERG1 TG mice ; (B) IHC performed 
on hERG1 TG mice confirm the HERG1-positive labelling. Original magnifications, 20x. 
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5. DISCUSSION 
 
 
BE is the main risk factor for EA and it represents a precancerous lesion that might 
progress towards malignancy. The exact progression rate of BE to EA is still unknown, 
but, since EA is still one of the worst cancers to treat (Ferlay J et al 2014) it is 
mandatory to identify molecular biomarkers that might lead to early diagnosis. Since 
BE is the most important precursor for EA, screening protocols have been 
recommended, although there are currently no evidences that BE screening effectively 
reduces EA incidence and mortality (Fitzgerald RC et al 2014). In search of novel BE 
biomarkers, we provide evidence that hERG1 channels can be considered novel markers 
of progression in BE patients. In particular, we showed that hERG1 is over-expressed in 
BE, confirming data obtained from a previous study conducted by our group (Lastraioli 
E et al 2006). In the present thesis, we demonstrated that hERG1 potassium channel can 
be easily detected in BE samples through IHC analysis using a monoclonal anti-hERG1 
antibody, which recognizes an extracellular epitope of the protein. We applied an 
immunihistochemical scoring method to evaluate hERG1 expression, based on the 
contemporary assessment of the percentage of labelled cells and the signal intensity, and 
we proved that hERG1 expression increases along BE progression to ED and EA. This 
was proven in separate cohorts of BE, ED and EA samples as well as in a subset of 
patients whose BE lesions progressed to ED or EA and for which matched BE and 
ED/EA samples were available. Performing a retrospective case-control study, we 
obtained the main translational result of this study, in which the association between 
hERG1 expression and development of adenocarcinoma was evaluated in samples from 
patients‟ biopsies collected at the diagnosis of BE. Patients enrolled in the study had a 
Chapter 1 
 
36 
 
Discussion 
follow up of at least 10 years, so that the progression to EA had been adequately 
monitored. Our data demonstrated a statistically significant association between hERG1 
expression in BE patients and risk of progression to EA (odds ratio = 3.70, 95% CI: 
1.40–9.82; P= 0.006). In other words, hERG1 expression identifies a group of patients 
whose lesions are suitable of progressing towards EA. Nevertheless, since the 
percentage of hERG1-positive progressed BE samples is not strikingly different from 
hERG1-positive not-progressed BE (although the statistically significant results 
reached), extreme caution should be applied, to take into account false-positive samples.  
We then tested whether hERG1 expression could be detected in different BE mouse 
models, in order to be exploited in the future for in vivo imaging and pharmacological 
studies. In particular, we confirmed hERG1 expression in the metaplastic cells arising in 
BE lesions of two different mouse models: a surgically-induced and a chemical-
transgenic model. Furthermore, in one mouse in which BE progressed to ED, the 
scoring of hERG1 expression increased. Interestingly, we also showed that the 
percentage of mice developing BE after the surgical procedure greatly increased (from 
36% to 100%) in transgenic mice over-expressing hERG1 gene in the GI tract. 
Although these results were obtained in a small set of animals, they might suggest a 
potential causative role of hERG1 in BE pathogenesis, a topic to be further studied in 
the future.  
In the recent years it came to kow that hERG1 plays a key role in several types of 
human cancer. In particular, hERG1 is a marker of advanced stage in colorectal cancers, 
contributing to identifying high risk TNM stage II patients (Lastraioli E et al 2004; 
Muratori L and Petroni G et al. 2016). In pancreatic and gastric cancers hERG1 is a 
prognostic biomarker also in early stages cancers, where it contribute to identify 
patients with worse prognosis (Crociani O et al 2014; Lastraioli E et al 2015). In the 
field of esophageal diseases, hERG1 channels might represent a progression factors that 
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identify high-risk BE patients and could therefore be useful for endoscopic surveillance 
in order to ensure a better follow up and early EA diagnosis. The aberrant expression of 
hERG1 in esophageal mucosa, even at early stages of esophageal cancerogenesis, could 
in turn modify cellular behavior switching on survival and proangiogenic signals, which 
in turn promote proliferation of BE metaplastic cells (Zhang Q et al 2014). To date, ED 
is the best histopathological progression marker but it is affected by several biases such 
as biopsy sampling error and subjective evaluation. For these reasons, other progression 
markers have been proposed over the years, such as aneuploidy and 9p and 17p loss of 
heterozigosity (LOH) (Weston AP et al 2001; Spechler SJ et al 2011; di Pietro M et al 
2015). Recently, immunohistochemical evaluation of P53 has been proposed as a 
progression marker, although the wide variation in the expression as well as the high 
false-negative and false-positive rates limit its usefulness (reviewed in Arcangeli A et al 
2015). In the present thesis, we provide evidence that immunohistochemical evaluation 
of hERG1 on biopsies obtained during endoscopic procedures might represent a valid 
and useful tool to better diagnose BE patients at high risk of progressing towards EA. 
Once validated, the possibility of including hERG1 channel to a panel of other BE 
progression predictive biomarkers could help to design the most useful surveillance or 
treatment protocol. 
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CHAPTER 2 
 
 
The role of gonadotropins in the genesis of malignant diseases, in particular 
gynecologic cancers, is still controversial. In this chapter we focused on luteinizing 
hormone receptor (LHR) and its role in endometrial cancer (EC). The increased ability 
of EC cells to undergo local invasion and metastatic spread, promoted by the binding of 
LH to its receptor, was demonstrated by our group in an orthotopic/menopausal mouse 
model. To date, EC was studied in vivo producing xenograft and orthotopic mouse 
models. For this purpose we have generated a LHR transgenic mouse model that over-
express hLHR in the female reproductive tract, in order to evaluating whether LHR 
over-expression is capable per se of inducing the development of EC. If these transgenic 
mice will be proven to be a good model for EC establishment, they will be used in the 
future to develop and test appropriate therapeutic interventions. 
 
 
1. INTRODUCTION 
 
 
1.1 GONADOTROPINS 
Gonadotropic hormones, such as luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH), are glycoprotein hormones released in a pulsatile manner from the 
hypophysis and act together to regulate gonadal function. The releasing of 
gonadotropins is regulated by the hypothalamus through the pulsatile secretion of 
gonadotropin-releasing-hormone (GnRH). Biological actions of LH and FSH include 
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stimulation of the maturation and function of the testis and ovary and regulation of 
gametogenesis and steroidogenesis (Catt K et al 1991). Testicular LH receptors (LHR) 
are expressed during fetal life, postnatally, at puberty, and adult life (Dufau ML 1998). 
In testis, LH acts on the Leydig cells to promote the production and secretion of 
testosterone (Segaloff and Ascoli 1992). In the ovary, LH promotes the maturation of 
follicular cells. After the initial inductive effect of FSH on LHR expression in the small 
follicles, LH enhances the subsequent stages of follicular development and 
steroidogenesis in granulosa and luteal cells (Richards JS et al 1988; Menon et al 2005). 
The LH peak promotes the ovulation by promoting the rupture of the preovulatory 
follicle and the release of the ovum. During fetal development, LHR is not detectable in 
the fetal ovary but is expressed in early neonatal life (Dufau ML 1998). FSH stimulates 
follicular maturation and estrogen production by granulosa cells in the ovary (Shemesh 
M et al, 2001). All the glycoprotein hormones are heterodimers containing a common α-
subunit and dissimilar β-subunits that confer biological specificity on the individual 
hormones. Gonadotropin receptors bind the intact heterodimeric hormone, but the 
individual hormone subunits are devoid of binding activity (Catt K et al 1991). Another 
gonadotropin is the human chorionic gonadotropin (hCG), which is synthesized and 
secreted by syncytiotrophoblastic cells of the placenta from the time of implantation, 
maintains the secretions of estrogen and progesterone by the corpus luteum during 
pregnancy. LH and (hCG) are structurally similar and share the same receptor (LHR). 
Due to its ability to bind both LH and hCG with high affinity, LHR is also known as 
LH/hCG receptor. 
 
1.2 LH RECEPTOR (LHR) 
The luteinizing hormone receptor (LHR) play a crucial role in the regulation of 
reproductive functions including ovarian steroidogenesis, ovulation in the female, and 
Chapter 2 
 
40 
 
Introduction 
testosterone production by the Leydig cells of testis (Ascoli et al 2002; Menon et al 
2005; Dufau ML 1998). 
LHR was demonstrated to be expressed in the follicles and corpus luteum  in the ovary 
and the Leydig cells of testes (Ziecik AJ et al 1986). The presence of LH/hCG receptors 
in the uterus was next demonstrated in rabbit, mouse and human (Sawitzke AL et al 
1991; Mukherjee D et al 1994; Reshef  E et al 1990). To date it is clear, that LH/hCG 
receptors are widely distributed in non-gonadal tissues including the female and male 
reproductive tract (oviduct, uterus and male accessory sex organs), placenta, mammary 
gland, brain, adrenal cortex, T lymphocytes and urinary bladder (Ziecik AJ et al 2007).  
 
1.2.1 Structure  
LHR is a single polypeptide chain with a structure that makes it a member of the 
rhodopsin/β2-adrenergic receptor subfamily of G protein-coupled receptors (GPCRs) 
and it is encoded by a single gene located in the short arm of chromosome 2 
(2p21) (Ascoli et al 2002; Rousseau-Merck MF et al 1990). These gene is about 80 kb 
in size and each consists of 10 introns and 11 exons (Atger et al., 1995; Tsai-Morris et 
al., 1991). Exons 1-10 and a portion of exon 11-encode a the N-terminal cysteine-rich 
region, all of the leucine-rich repeats (LRRs), and the N-terminal end of the hinge 
region of the extracellular domain. The remainder of exon 11 in LHR encodes the seven 
transmembrane helices, three extracellular loops, three intracellular loops, and an 
intracellular C-terminal tail (Puett D et al 2005). In agreement with the orientation of 
other GPCRs, we can recognize three distinct domains in the LHR, a large extracellular 
N-terminal domain, a central region containing seven transmembrane segments 
connected by three intracellular loops and three extracellular loops and a short 
intracellular C-terminal tail (Figure 1). 
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Figure 1: Stylized rappresentation of the LH recepror with its intracellular, extracellular and 
transmembrane potions. 
 
The long extracellular domain contains about 341 residues and binds LH and hCG with 
high affinity (Wang Z et al 1993). The exodomain contains leucine-rich repeats (LRRs) 
of 22–29 amino acids, that forms a α/β horseshoe fold, which is important for the 
protein-protein interactions (Dufau ML et al 1998; Enkhbayar P et al 2004), The LRRs 
domains of the LH, FSH, and TSH receptors share sequence similarities of about 43% 
within exons 2–8. However, the similarity diminishes at the N- and C-terminal domains 
of the extracellular region with the presence of amino acid inserts in the FSH and TSH 
receptors, suggesting that these regions may be important for denoting hormone 
specificity (Dufau ML et al 1998). Moreover, six potential glycosylation sites have been 
identified in human LHR which are required for the proper folding of the protein 
(Menon KMJ et al 2012). 
The LHR receptor is palmitoylated on two cysteine residues in the C-terminal tail. 
Receptor palmitoylation is believed to provide two anchoring sites for the cytosolic tail 
onto the plasma membrane (Moench SJ et al 1994). Although abrogation of the 
palmitoylation sites does not reduce the ability of the receptor to bind ligand or mediate 
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activation of adenylate cyclase or inositol phosphate breakdown, the absence of 
palmitoylation increases the LH/hCG-induced internalization of the receptor. It is 
reasonable to speculate that the receptor, after binding hormone, might undergo 
depalmitoylation to facilitate its internalization (Bradbury FA et al 1999; Menon KMJ 
et al 2004). The C-terminal sequence also contains several serines and threonines that 
are amenable to phosphorylation by protein kinase A. In addition, the intracellular 
portion contains consensus sites for protein kinase C phosphorylation, and tyrosine 
kinase phosphorylation (Dufau ML et al 1998). 
The seven transmembrane helices are connected by three extracellular and three 
intracellular loops. The receptor contains cysteine residues in the first and second 
extracellular loops, as do other members of the superfamily. These residues form an 
intramolecular disulfide bridge that stabilizes the helical seven-transmembrane structure 
(Dufau ML et al 1998). 
 
1.2.2 LHR signaling 
The signal transduction pathways of the gonadotropin receptors include activation of 
both the adenylate cyclase and phospholipase C systems. Like other members of GPCR 
family, the intracellular loops of LHR interact with G proteins. G proteins are 
heterodimeric complexes made up of α, β and γ subunits, able to bind GTP and GDP. 
Binding of LH to LHR results in a conformational change in the receptor that is 
transmitted to the G protein and lead to α subunit cycle from inactive (GDP-bound) to 
active (GTP-bound) (Digby GJ et al 2006). Active G protein heterotrimers dissociate 
into α-GTP and βγ subunits that interact with other intracellular proteins to continue the 
signal transduction cascade.  LH mediates its action on the endometrial cells via two 
intracellular second messenger systems. The first one involves the activation of 
adenylate cyclase  and the subsequent production of cAMP and the second one the 
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stimulation of phospholipase C (PLC) and the activation of protein kinase C (PKC) 
(Ziecik AJ et al, 2007) (Figure 2). 
 
Figure 2: Rappresentation of the main signaling pathways promoted by the binding of LH to 
LHR. The activation of LHR leads to the activation of PKA and phospholipase C pathways. 
 
LHR expressed in target tissues is known to respond to a physiological concentration of 
LH or an equivalent concentration of hCG by mediating the activation of adenylate 
cyclase (Menon KMJ et al 1974). At superphysiological concentrations, LH/hCG has 
been shown to stimulate phospholipase C, leading to inositol phosphate breakdown and 
the consequent production of inositol trisphosphate (IP3) and diacylglycerol (DAG). 
IP3 is a stimulator of calcium mobilization, whereas DAG is a potent stimulator of 
protein kinase C (PKC) (Nishizuka Y et al 1984).  
Increased amounts of second messenger were associated with increased concentrations 
of endometrial cyclooxygenase (COX-2) and its metabolite PGF. The physiological 
significance of PGF production during the postovulatory phase of the oestrous cycle is 
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not known. Secretion of PGF at this early stage of the cycle may be necessary for the 
movement of the early embryo from the Fallopian tube to the uterus (Shemesh M et al, 
2001). LH may also act through cAMP to regulate progesterone synthesis and its 
metabolism (Bonnamy PJ et al, 1989). 
LH activates both the cAMP and phospholipase C pathways and the effect of LH on 
both pathways at each stage of the cycle is correlated with the amount of LHR present 
in the tissue. Activation of these signalling pathways is associated with an increase in 
the expression of cyclooxygenase and production of PGE in the myometrium (Shemesh 
M et al, 2001). In myometrium high concentration of LHR, induced by estradiol, 
resulting in an increase in cAMP may serve to allow the relaxing of the uterus during 
the luteal phase (Shemesh M et al, 2001). 
The LH/hCG receptor has also been shown to mediate activation of the mitogen-
activated protein kinase (MAPK) and Janus kinase-signaling pathways (Srisuparp S et 
al, 2003, Carvalho CR et al, 2003). It has been suggested that LH-promoted MAPK 
stimulation may result in the desensitization of LH-stimulated steroidogenesis in 
granulosa cells (Amsterdam A et al, 2002; Menon KMJ et al 2004). 
 
1.3 MOUSE MODELS 
Genetically engineered mouse (GEM) models have significantly contributed to the 
understanding of cancer biology and its molecular mechanisms. They have been proven 
to be useful in validating gene functions, identifying novel cancer genes and tumor 
biomarkers, gaining insight into the molecular and cellular mechanisms underlying 
tumor initiation and multistage processes of tumorigenesis, and providing better clinical 
models in which to test novel therapeutic strategies. However, mice still have 
significant limitations in modeling human cancer, including species-specific differences 
and inaccurate recapitulation of de novo human tumor development (Cheon DJ et al 
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2011). Mice share with humans many anatomical, cellular, and molecular characteristics 
that are known to have critical functions in cancer, such as an immune system, maternal 
effects in uterus, imprinting of genes, and alternative splicing. 
 
1.4 GENETICALLY ENGINEERED MOUSE MODELS (GEM) 
With the availability of the complete sequence of the mouse genome, technology to 
manipulate the mouse genome, and well-defined inbred strains, the ability to engineer 
mice is impressive. Experiments can be undertaken to assess the outcome when the 
function of a gene is lost, mutated, underexpressed, or overexpressed in the appropriate 
cell types in vivo (Walrath JC et al 2010). Mutagenesis studies in the mouse have 
identified new cancer-causing mutations that can then be confirmed in studies of human 
cancers. 
 
1.4.1 Loss of gene function in GEM 
Studying the loss of function of genes provides insight into understanding the biological 
functions for which the protein product is required. Loss-of-function studies most 
commonly use “knockout” strategies to remove the gene of interest by engineering 
constitutive or conditional deletions in the gene.  For genes that span large genomic 
regions, deletion of the first few exons encoding the start codon is often sufficient to 
block transcription or translation into a functional protein product.  The use of knockout 
strategies have been critical in understanding cause and effect relationships in cancer 
development, and can be applied to the assessment of many gene classes, including 
oncogenes, tumor suppressor genes, and metabolic (“housekeeping”) genes (LePage DF 
and Conlon RA 2006).  
Knockout mouse models: Conventional knockout vectors contain a positive selectable 
marker, usually neomycin (Mansour et al 1988). This allows the replacement of specific 
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genes with Neo through homologous recombination between the targeting vector and 
the cognate sequence in the recipient clonal embryonic stem (ES) cell genome after the 
vector is transferred into these cells by electroporation. Only neomycin resistant ES 
cells generated by homologous recombination can grow under selection. The first step 
of this technique involves the isolation of a ES cell line that contains the desired 
mutation. The second step is to use these ES cells to generate chimeric mice that are 
able to transmit the mutant gene to their progeny. This is accomplished by injecting ES 
cells that contain the desired targeted mutation into a blastocyst. These blastocyst are 
then surgically transferred to a pseudopregnant foster mother to allow the embryos to 
come to term. To facilitate isolation of the desired progeny, the ES cells and recipient 
blastocysts are derived from mice with distinguishable coat-colour alleles (for example, 
ES cells from agouti brown mice and blastocysts from black mice). The extent of the 
contribution of ES cells to the formation of the chimeric mouse can be evaluated by 
visual assessment of coat-colour chimerism (Figure 3). ES cell contribution to the 
germline can be evaluated by observing the coat colour of the progeny that is derived by 
breeding the chimeric mouse with black wild type mice (Capecchi MR 2005).  
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Figure 3: Generation of mouse germline chimaeras from embryonic stem cells that contain the 
desired targeted mutation. 
 
With conventional knockouts, loss of a vital gene can often lead to embryonic lethality 
or adult sterility, making it impossible to study the gene in the disease context. In 
addition, ablation of the gene of interest in the entire body does not mimic spontaneous 
tumorigenesis in humans, where tumors evolve in a wild-type environment, and the 
timing of gene loss may be a critical factor in disease development (Walrath JC et al 
2010).  
Mouse conditional gene mutations: to circumvent conventional knockout limitations, 
sophisticated conditional genetic engineering technology has been developed to create 
systems where genetic events can be tightly controlled spatially and temporally such as 
Cre/loxP system and TET system. 
Cre/LoxP system: The Cre/loxP system mediates site-specific DNA recombination and 
was originally described in bacteriophage P1. Bacterial Cre enzyme is site-specific 
recombinase that catalyze specific recombination between defined 34 bp DNA-
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sequences (loxP).  In the presence of Cre protein expression any DNA sequence flanked 
by two loxP sites will either be excised (if loxP sites are in same orientation) or inverted 
(if loxP sites are in opposite orientation) (Figure 4) (Stricklett PK et al, 1999). A gene 
flanked by 2 loxP sites is called “floxed gene”.  
 
Figure 4: Schematic of Cre-mediated recombination of a gene fragment flanked by loxP sites. 
The gene is either excise or inverted if the loxP sites are in the same or opposite orientation, 
respectively. 
 
In most of the studies a floxed STOP sequence is inserted 5′ to a reporter gene. Upon 
Cre-mediated recombination, the STOP sequence is excised allowing the expression of 
the reporter. A major advantage of the Cre/loxP system lies in its relative simplicity. 
First, no cofactors are required for Cre activity. Second, loxP target sites are small and 
easily synthesized. Third, Cre is a very stable protein. Finally, and most important, it is 
easy to generate DNA constructs with any promoter of interest driving Cre expression. 
This permits controlling the tissue site, and possibly the timing, of Cre expression and 
resultant gene disruption. By temporally and spatially controlling expression of the 
recombinase, it is then possible to temporally and spatially control deletion of the gene 
of interest, overcoming interference from developmental abnormalities and lethality 
(Branda CS and Dymecki SM; 2004). Mice carrying the Cre recombinase under control 
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of a tissue-specific promoter are crossed with mice carrying the gene of interest flanked 
by loxP sites to conditionally knockout the gene in a specific tissue or at specific times 
during development. 
TET system: The tetracycline-controlled transcription activation system was shown to 
function as an efficient genetic switch in a variety of eukaryotic cells, including 
mammalian cells. It also allows effective control of gene activities at the level of the 
organism (Baron U et al 1997).  This system is composed of a transactivator and an 
effector. One of the key components of the tet system is the tetracycline-controlled 
transactivator (tTA), a fusion protein between the DNA-binding domain of the repressor 
of Escherichia coli tetracycline resistance operon (Tet Repressor Protein) and a C-
terminal portion of the herpes simplex viron protein 16 (VP16) that contains domains 
capable of activating transcription (Baron U et al 1997). The tTA binds to the 
tetracycline operator (tetO) that controls the activity of the human cytomegalovirus 
promoter (CMV promoter) driving conditional gene expression. That system is named 
Tet-Off system because in the presence of tetracyclin, tTA is prevented from binding to 
tetO and thus transcription is abolished. In the absence of the effector tetracycline, tTA 
will activate transcription from a suitably engineered promoter by binding to an array of 
tet operator sequences positioned upstream. In the Tet-On system, the tetracycline-
repressor has been mutated (rtTA) such that it is only in the proper conformation for 
association with tetO when it is bound to tetracycline, thus inducing expression of the 
gene in the presence of drug (Stricklett PK et al, 1999). 
 
1.4.2 Gain of gene function in GEM 
Mouse constitutive transgenic models: gain-of-function studies are often used to study 
oncogenes in mouse models.  Transgenic or knockin animals constitutively 
overexpressing an oncogene can be used to study how the oncogene drives 
Chapter 2 
 
50 
 
Introduction 
tumorigenesis in vivo. Transgenic animals have been very useful in studying many 
oncogenes. Transgenic animals are created by the pronuclear injection of transgenes 
directly into the pronucleus of fertilized oocytes, followed by implantation into 
pseudopregnant females (Macleod KF, Jacks T et al 1999; Porret A et al 2006) Briefly, 
the main steps of this technique include: the coupling of females, treated with FSH and 
hCG, with fertile males; their sacrifice for the removal of zygotes, the injection of the 
construct, containing the gene/cDNA of interest, into the male pronucleus and the 
subsequent reimplantation of survived embryos in fosters females (females coupled 
with sterile males ready to carry a pregnancy). The transgene is randomly incorporated 
into the genome and thus can incorporate into a gene necessary for development or 
fertility, causing deleterious effects and limiting the usefulness of the transgenic model. 
Furthermore, the epigenetic regulation of gene expression in the region surrounding the 
transgene integration can affect transgene expression levels and often result in silencing. 
Therefore, multiple founders must be screened to confirm adequate and specific 
expression of the transgene (Figure 5). 
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Figure 5: Generation of transgenic mice. In order to express a transgene in vivo, the investigator 
first makes a construct containing the transgene being evaluated. Then fertilized eggs are 
washed out of the oviducts of female mice. They are then microinjected under direct 
visualization and implanted into the uterus of pseudopregnant female mice. The genotype of the 
pups that are produced is evaluated in tail biopsy–derived DNA using PCR reactions (modified 
picture from Elias JA et al 2003). 
 
To circumvent transgenic limitations associated with random insertion, knockin mice 
are created by inserting a gene of interest into a specific region of the genome using 
homologous recombination techniques, much like those used when creating knockouts. 
The Rosa26 locus is commonly used as an insertion site for knockin animals because it 
is devoid of essential genes and allows for good expression of the transgene (Friedrich 
G and Soriano G 1991). While transgenics have the potential for multiple insertions of 
the transgene, knockin animals carry only one copy of the transgene. This approaches 
can also be used to replace a normal gene copy with a mutated version of the gene to 
examine specific mutational events in the context of normal control of the gene (Lang 
GA et al 2004). 
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Mouse conditional overexpression models: transgenic and knockin expression of 
deleterious genes may lead to lethality, sterility, and developmental defects that impede 
study of the gene of interest in cancer, as seen with many conventional knockouts. 
Therefore, spatial and temporal control of transgene and knockin expression may be 
necessary to circumvent these limitations. Conditional transgenics and conditional 
knockins can be created using tissue-specific promoters to constitutively drive 
expression or created by inserting a strong translational and transcriptional termination 
(STOP) sequence flanked by loxP sites in between the promoter sequence and the gene 
of interest (Lakso M et al., 1992). Examples of commonly used STOP cassettes are the 
lox-STOP-lox in which multiple STOP sequences are arrayed between loxP sites 
(Jackson EL et al , 2001) and the NEO-STOP cassette in which the neomycin resistance 
gene and a STOP sequence is inserted between loxP sites (Dragatsis I and Zeitlin S, 
2001). The presence of the STOP sequence blocks transcription of the gene of interest. 
However, in the presence of Cre recombinase, the STOP cassette is removed, allowing 
expression. Since gene expression is dependent on excision of the STOP cassette and 
recombinase expression, gene expression can be spatially, temporally, and inducibly 
controlled with the Cre systems (Stricklett PK et al, 1999). 
 
1.5 MOUSE MODELS FOR GONADOTROPINS AND THEIR RECEPTOR 
The main target of gonadotropins in females is the ovary, maturation of which is 
triggered by LH and FSH at puberty. It is largely agreed and confirmed by animal 
models lacking FSH, LH or their receptors that the gonadotropins are not critical for the 
prenatal female uro-genital development. Nevertheless, loss-of-function mutations in 
any of the gonadotropins or their receptors lead to delayed or interrupted progression of 
puberty, hypogonadism and consequently infertility. The potential role of gonadotropins 
in initiation and/or progression of ovarian tumors has been discussed for 
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decades. Intriguingly, in genetically modified animals both excess and lack of 
gonadotropin action have been linked with tumorigenesis including germ cell, sex-cord 
and surface epithelial tumors (Peltoketo H et al 2011). To study the roles of only FSH in 
mammalian reproductive physiology, Kumar and coll. developed FSHβ null mice and 
hence lack a FSH heterodimer (Kumar TR et al 1997). Subsequently, using transgenic 
mouse model overexpressing hCG it was demonstrated that female mice are very 
sensitive to tumorigenic effects of the elevated LH/hCG action, and consequent 
elevation of ovarian steroidogenesis. A multitude of tumours and 
altered endocrine functions were observed in gonads, pituitary gland, mammary gland 
and adrenal cortex of these animals (Huhtaniemi I et al 2005). Indeed, LH knockout 
males and females were infertile and demonstrated reduced size testes and accessory 
glands, consistent with decreased serum and intra-testicular testosterone levels, and 
pituitary serum FSH levels were unaffected (Ma X et al 2004). In TG mice expressing 
the mouse inhibin α-subunit promoter/SV40 T-antigen fusion gene elevated LH levels 
likewise act as tumour promoter and induce gonadal and adrenal tumorigenesis (Mikola 
M et al 2003). In addition, mice deficient of the inhibin α-subunit gene develop 
mixed granulosa/Sertoli celltumours in the presence of LH and FSH (Kumar TR et al 
1996). The LHR knockout mouse model, developed by Huhtaniemi group, allowed to 
identify the specific LH-dependent steps of male and female sexual differentiation and 
adult gonadal functions. In particular, it was demonstrated that in each sex, the 
intrauterine sex differentiation is independent of LH action, but it has a crucial role 
postnatally for attaining sexual maturity (Zhang FP et al 2001). Overall, the loss and 
gain-of-function mutations affecting LH/hCG action in genetically modified mice have 
greatly expanded our knowledge about functions of the regulation of gonadal function. 
However, the rather robust TG and KO models currently available do not fully simulate 
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the genetic aberrations detected in human gonadotrophin action and in gynecological 
diseases. 
 
1.6 EDOMETRIAL CANCER MOUSE MODELS 
The endometrium is a classical hormone-dependent tissue and most of the endometrial 
adenocarcinomas are hormone-dependent tumors. A high percentage of these tumors 
express the estrogen, progesterone and LH receptors. Investigators have, therefore, 
aimed at targeting steroid hormone receptors by the development of novel sub-stances. 
For testing and characterization of these new substances appropriate models have to be 
available. Moreover, mouse models historically have proved to be particularly useful in 
studying the effects of developmental exposure to hormones, particularly estrogens. The 
neonatal mouse has been proposed as a model for hormonal carcinogenesis of the 
endometrium. Particulary, CD-1 mice appear to be an excellent model to test for 
developmental toxicity of estrogens, thereby evaluating the capacity of test substances 
to induce hormonedependent endometrial cancers. CD-1 mice respond to treatment with 
N-methyl-N-nitrosourea (NMU) or estradiol with the development of endometrial 
cancers within 30 weeks. This process is significantly accelerated if mice are treated 
with both agents simultaneously (Niwa K et al 1991; Vollmer G et al 2003). In 
comparison to human endometrial carcinogenesis, histopathological examinations 
revealed that these tumors develop from various preneoplastic, hyperplastic lesions, 
resembling the human situation (Niwa K et al 1991). For the development of atypical 
hyperplasia the cooperative action of estradiol and NMU is favorable (Niwa K et al 
1996). 
As previously described, a significant rate of PTEN gene mutations has been reported 
for human endometrial adenocarcinoma (Risinger JI et al 1997). Unlike the human 
situation, in pten + / − -mice neoplasia of the skin and brain were notably absent, 
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whereas the observed changes in the endometrium were very consistent (Podsypanina K 
et al. 1999). In order to better understand the biological role of this tumor suppressor 
gene, transgenic PTEN knock-out mice have been created. A Pten− / − mutation is 
lethal presumably due to defective chorio-allantoic development but surprisingly, the 
mutation of one allele is sufficient to cause neoplasia in multiple organ systems in these 
pten + / − -mice (Suzuki A et al 1998). Stambolic et al.  proposed pten + / − -mice as a 
model for endometrial adenocarcinomas which develop in women with unopposed 
estrogen stimulation. These patients rather commonly suffer from loss of heterozygosity 
at the PTEN locus and/or mutations in all stages of endometrial hyperplasia (Stambolic 
V et al 2000). Pten +/− -mice represent a promising endometrial cancer model, because 
of the similarity to hereditary human endometrial cancer (Vollmer G et al 2003).  
Moreover, xenograft mouse models have been used in preclinical studies for their 
comparatively low cost and rapid, predictable tumor growth. An orthotopic xenograft 
mouse model of EC was developed in our lab in order to better study the capability of 
EC cells to undergo local invasion and metastatic spread (Pillozzi et al 2013). Pillozzi et 
al. evaluated the effect of LHR on invasiveness of EC, using Hec1A cells stably 
transfected with, and hence over-expressing, the human LHR (Hec1A-LHR cells).  The 
model consists in athymic nu/nu mice which received an implant of very small tumor 
block in the uterine wall. The tumor blocks we implanted were obtained from 
subcutaneous masses obtained after injection of either Hec1A-LHR or Hec1A cells (not 
expressing LHR). Athymic nude mice are a very good model for this aim, since they 
display severe deficiencies in reproductive function such as delayed ovulation and 
gonadotropins are totally absent. In order to make the model closer to the condition of 
menopause, in which there are high levels of circulating LH, the mice were treated daily 
with high doses of LH. The use of such model allowed to conclude that the over-
expression of the LHR on the membrane of EC cells, is critical to make EC cells to 
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become more aggressive, and capable of invading the myometrium as well as 
surrounding organs, and the concomitant over-expression of the LHR and high levels of 
serum LH, make EC cells capable of reaching the lung and give rise to lung metastases 
(Pillozzi S et al 2013). 
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2. MATERIALS AND METHODS 
 
2.1 Generation of LHR transgenic mice 
In order to assemble the construct, the luciferase gene was amplified from 
pGL4.51[Luc2/CMV/Neo] vector (Promega) and the hLHR gene from Hec1A cells by 
polymerase chain reaction (PCR). For both the PCR we used Phusion High-Fidelity 
DNA polymerase (Finnzymes, New England Biolabs). The reactions were made using 
the touchdown protocol starting from 70°C with a 2°C decrease each 4 cycles, till 52°C. 
The mogp-1 promoter was amplified by PCR from BL-1A stem cells derived from 
SV129 mice. The reaction was made using Expand Long Template PCR system 
(Roche) and the PCR program starts with an incubation at 94°C for 2 min, followed by 
28 cycles, each involving denaturation at 94°C for 10 s, annealing at 60°C for 30 s, and 
extension step at 68°C for 2 min. 
The 8000-bp mogpLuc2AhLHR construct was excised from the pBluescript SK+ vector 
and it was microinjected into the male pronucleus of fertilized zygotes of FVB mice. 
Fertilized zygotes were obtained from mating of FVB mice and implanted into 
pseudopregnant FVB females. The procedure was done at LIGeMA (University of 
Florence, Italy), following standard protocol. Resulting puppies were screened by PCR 
analysis of DNA extracted from tails. Two mice founders were found, one male and one 
female. Transgenic mice were maintained in heterozygous in FVB background. Mice 
were kept in plastic cages and maintained under conventional conditions at LIGeMA, 
University of Florence. 
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2.2 Screening PCR of transgenic mice 
Transgenic mice were genotyped by end point PCR analysis of genomic tail DNA. The 
DNA was extracted using the Chelex extraction protocol by incubation of a 0.2 cm of 
mice tails in 150 μl of 10% (w/v in water) Chelex 100 resin (BIO-RAD) for 4 hours at 
56°C and 30 minutes at 98°C. The presence of the hLHR gene was checked on mouse 
tail genomic DNA by amplification of a 350 bp fragment using the forward 5‟ 
GGCTGAAGAGCCTGATCAAATACA 3‟ (ScrLucLHRup) and reverse 5‟ 
CGCATGTTAGCAGACTTCCTCT 3‟ (ScrLucLHRdn) primers at final concentration 
of 300 nM. These primers recognize a reagion into a luciferase sequence. The reaction 
was performed using the PCR SuperMix (Platinum PCR SuperMix, Invitrogen). PCR 
program start with denaturation at 94° for 2 min, followed by 35 cycles at 94°C for 30 
sec, 58°C for 30 sec, 72°C for 30 sec, and a final extension cycle at 72°C for 10 min. 
 
2.3 RNA extraction and reverse transcription 
Uterus and ovary of  both wild type and transgenic animals has been dipped in TRIzol 
Reagent (Invitroge) and homogenized to isolate total RNA according to manufactorer‟s 
protocol. RNA concentrations were determined using spectrophotometer by measuring 
the absorbance at 260 nm (A260). The ratio of the readings at 260 nm and 280 nm 
(A260/A280) provides an estimate of the purity of RNA with respect to contaminants 
that absorb in the UV, such as protein and phenol. Pure RNA has an A260/A280 ratio of 
1.8–2.1. Before reverse transcription, RNA integrity was evaluated by agarose gel (1%) 
electrophoresis. 
Reverse transcription was done from 1 µg of RNA using 200U/µL of SuperScript II 
Reverse Transcriptase (Invitrogen), adding for each sample 500 µmol/L of 
deoxyribonucleotide triphosphate (dNTP) (Invitrogen) and 15 ng/µL of random primers 
(Invitrogen). The reaction starts preparing a mix with: 
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 1µg of RNA 
 2 μl of Random Primers (diluited 1:20 from the stock solution) 
 1 µl of dNTPs (10mM) 
 ddH₂O till a final volume of 12 µl 
The mix was incubated in a thermal cycler at 65°C for five minutes, and then 
immediately placed on ice for five minute. Then, the following was added to the tube: 
 4 µl of Buffer 5X First Strand 
 3 µl of ddH₂O 
The mix was heated at 25 °C for 2 min and than added with the SuperScript II. The mix 
was incubated as follows: 
 
 
 
 
 
2.4 Real time PCR 
hLHR expression was evaluated by real-time quantitative PCR (qPCR) using 1µL of 
cDNA. QPCR involves the use of fluorescence to detect the threshold cycle (Ct) During 
PCR. When the level of fluorescence signal gives over the background and is in the 
linear portion of the amplified curve. This Ct value is responsible for the accurate 
quantisation of qPCR. We used Sybr Green Master Mix Kit (Applied Biosystem). The 
primer sequences for hLHR are: 5‟-TGCCTACCTCCCTGTCAAAG-3‟ forward 
primer; 5‟-TTGAGGAGGTTGTCAAAGG-3‟ reverse primer. β-actin was used as 
housekeeping gene. The primer sequences for β-actin are: 5‟-
GGGGTGTTGAAGGTCTAAA-3‟ forward primer; 5‟-
Temperature (°C) Time (min) 
25°C 10 
42°C 50 
70°C 15 
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GATCTGGCACCACACCTTCT-3‟ reverse primer (Fiore A et al 2013). All the primers 
were used at final concentration of 300 nM. PCR program start with an incubation at 95 
°C for 10 min, followed by 40 cycles of amplification: denaturation at 95 °C for 15 s 
and annealing–extension step at 60 °C for 1 min. Each reaction was performed in 
triplicate. Melting curve analysis of the amplicons were performed to exclude the 
amplification of a specific products or primer-dimer artefacts. LHR expression values of 
the samples were normalized on Hec1A cells. The relative quantification of LHR gene 
expression was performed by the ΔCt method. 
 
2.5 Analysis of uterine morphometry 
The reproductive tract of 12 female mices (3 wild type and 9 transgenic) was rapidly 
excised and fixed in 4% formaldehyde for 4 hours, transferred in a graded series of 
alcohol, embedded in paraffin, cut lengthwise at a thickness of 6 µm and put on 
positive-charged slides to perform analysis of uterine morphometry and 
immunohistochemistry (IHC). 
Samples were stained with Hematoxilyn/Eosin standardized protocol. The uterine radius 
was measured from the serosal side to the apical surface of the luminal epithelium. The 
muscle layer was considered the inner circular layer. The luminal epithelial height was 
measured from the basement membrane to the apical surface. All measurements were 
performed using a light microscope (Leica DMR, Germany) equipped with Leica DC 
Viewer and Leica Qwin. The measurements were taken from the slide that showed the 
uterine cavity and two measurements per area were analyzed. 
 
2.6 Immunohistochemistry 
After dewaxing and dehydrating the sections, endogenous peroxidase were blocked with 
1% H2O2 solution in phosphate-buffered saline. Then, antigen retrieval was performed 
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by heating the samples in a microwave oven at 600 watt in citrate buffer pH 6.0 for 12 
minutes. Sample were permeabilized with a 0,1% TRITON X100 in UltraVBlock 
solution (LabVision) and incubated overnight at 4C with the primary antibodies: anti-
c-myc (monoclonal antibody, Santa Cruz Biotechnology, Santa Cruz, CA), anti-Ki67 
(monoclonal antibody, Dako) and anti--SMA (monoclonal antibody, Dako), at a 1:100 
final dilution. Immunostaining was carried out with a commercially available kit 
(PicTure-Max polymer Detection kit, Invitrogen) according to manufacturers‟s 
instruction. C-myc and -SMA expression were evaluated with an estimate of the 
percentage of immunoreactive cells and samples were classified as positive when the 
percentage of labeled cells was greater than or equal to one. Ki67 expression was 
evaluated in three different areas of the section: percentage of stained cells in luminal 
epithelium, in glandular epithelium and in stroma. 
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3. AIMS OF THE STUDY 
 
 
This study was aimed to investigate the role of LH receptor in the process of in vivo EC 
carcinogenesis. For this purpose we have generated a transgenic mouse model over-
expression LHR in gynecological tract with the aim of determining whether LHR over-
expression is capable of inducing the development of EC. Tissues of transgenic mice 
will be taken and evaluate.  
This model will be further used evaluating the effect of LHR over-expression on the 
susceptibility to carcinogen agents.  If the LHR transgenic model will be proven to be a 
good model for EC establishment it will be used for pharmacological tests. 
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4. RESULTS 
 
 
4.1 Production of LHR constitutive transgenic murine model 
In order to produce a LHR transgenic (TG) mouse model in our laboratory we 
previously produced a construct incorporating the hLHR cDNA under the control of 
Mogp-1 mouse promoter. Mogp-1 gene is active in the oviduct, ovary, uterus and 
vagina of mice (Miyoshi et al., 2002). At the 3‟of the hLHR cDNA it was placed the  
sequence coding for the myc-tag. For the in vitro and in vivo assessment, we included 
the luciferase reporter gene in the construct whose synthesis occurs equimolar to LHR, 
due to use of  the 2A peptide sequence, which is separated in two fragments during the 
translation (Tirichas et al., 2008). The 2A peptide is inserted in frame between the 
cDNA of LHR and the cDNA of Luciferase. All the characteristics of the final construct 
are represented in figure 6.  
 
 
Figure 6: Picture of the construct used for the generation of a mouse model overexpressing 
LHR. The LHR and the Luciferase sequences are inserted in frame as a single cDNA, separated 
by a specific virus sequence (2A sequence), allowing the production of the two single proteins 
in an equimolar manner. 1 and 2 are the primers used for screening by PCR of founders mice. 
 
The proper functioning of this construct was tested in in vivo experiments transfecting 
HEC1A endometrial cancer cells. The transfection was performed in duplicate using 
either the pBlueScript SK+ vector containing the complete construct 
Chapter 2 
  
62 
 
Results 
(mogpLuc2AhLHR) and the empty pBlueScript SK+ plasmid, used as negative control. 
Data obtained from the analysis with the luminometer showed an increase of RLU 
(Relative Light Unite) in cells transfected with mogpLuc2AhLHR construct, compared 
to those transfected with the empty vector (Figure7A), index of a proper functioning of 
the mogp-1 promoter and an appriopriate production of  luciferase. Moreover, in order 
to verify the proper hLH receptor placement on the plasma membrane we performed 
immunifluorecence experiments in HEC1A cells transfected with the vector containing 
mogpLuc2AhLHR construct. For this assessment we used anti-myc primary antibody as 
detailed in Materials end Methods. Although the low transfection efficiency the hLHR 
is properly placed on the membrane (Figure 7B, white arrows). 
 
Figure 7: A) Data coming from the analysis to the luminometer after transfection of Hec1A 
cells. B: Confocal microscope images showing in green the presence of LHR in the membranes 
(Indicates with white arrows). Immunofluorescent staining with Ab I anti-myc, 1:100 and Ab II 
Alexa 488, 1:500. The nucleus are colored with DAPI. 
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Subsequently, the construct containing the cDNA of LHR was microinjected into the 
male pronucleus of mouse zygotes, which has been then reimplanted in the oviduct of 
fosters females. Briefly, the main steps of this technique include: the coupling of CD1 
females, treated with FSH and LH, with fertile males; their sacrifice for the removal of 
zygotes, the injection of the construct into the male pronucleus and the subsequent 
reimplantation of survived embryos in fosters females (females coupled with sterile 
males ready to carry a pregnancy). Resulting puppies were screened by PCR analysis of 
DNA extracted from tails. Two out of five mice born from the reimplantation were 
found positive at the screening, one male and one female (respectively named as LHR-
100 and LHR-200), and they were used as founders mice (Figure 8).  
 
Figure 8: Elettrophoretic analysis for the screening of transgenic mice shows the presence of 2 
founders in lanes 1 and 4 (agarose gel). Samples in lanes 1-5. In lane 6, positive control. In lane 
7, negative control. 
 
4.2 Characterization of LHR transgenic mice 
The two founders mice were mated with FVB wild type animals in order to maintain 
and breed hemizygous transgenic mice and to gave origin at the two transgenic 
colonies: TG-LHR-100 and TG-LHR-200. In terms of number of puppies, no 
differences were found between transgenic mice and FVB wt animals (Figure 9), though 
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the males of the LHR-100 seems to have some fertility issues, because only one male of 
that line produced a litter. 
 
Figure 9: Column plot representing the minimal differences between the mean number of 
puppies of FVB WT mice and TG-LHR mice. 
 
To evaluate the expression of hLHR gene in TG-LHR mice we sacrificed three 
transgenic mice and three FVB wt mice with the same age (< 12 months) and uterus, 
ovary, liver and spleen were taken. These organs were processed for RNA extraction 
and retrotranscription in cDNA (as detailed in Materials and Methods). RQ-PCR 
analysis showed that TG mice had hLHR mRNA high expression in the uterus, higher 
compared to wt controls. In particular, performing t-test analisys it was emerged that the 
different expression of hLHR between transgenic and wt animals was statistically 
significant (p=0,018)(Figure 10). 
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Figure 10: Graph representing LHR mRNA expression values in the uterus of TG-LHR-200 
<12-months-old mice VS wt mice of the same age. 
 
The expression of the transgene was found higher also in the liver of TG-LHR mice 
compared to the liver of wt animals (Figure 11). The different expression between 
transgenic and wt animals was statistically significant (p=0,023). This data may suggest 
the ectopic expression of the transgene. 
 
 
 
 
 
 
 
Figure 11: Graph representing LHR mRNA expression values in the liver of TG-LHR-200  
<12-months-old mice VS wt mice of the same age. 
 
Moreover, the expression of the hLHR mRNA was higher in the ovary and spleen of the 
TG-LHR mice compared to the wt animals, though the different expression between 
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transgenic and wt animals was not statistically significant (Figure 12). Although, 
normalizing the LHR expression value of the TG mice to the wt mice it emerged that 
the expression is higher in both ovary and spleen of transgenic animals. 
 
 
 
Figure 12: Graphs representing LHR mRNA expression values in the ovary (left panel) and 
spleen (right panel) of TG-LHR-200  <12-months-old mice VS wt mice of the same age. P 
values: ovary p=0,33; spleen p=0,22. 
 
To confirm the over-expression of hLHR in TG-LHR mice we performed also an 
immunihistochemestry analysis on uterus slides of a 12-years-old TG mouse using anti-
c-myc primary antibody (as detailed in Material and Methods). As shown in figure 10 
the labeling is present in TG-LHR-200 mouse (Figure 10A) and in TG-LHR-100 mouse 
(Figure 10B), but it is absent in wild type mouse (Figure 10C), that confirm the 
presence of the LHR transgene in endometrium of TG mice. 
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Figure 10: A: Graph representing LHR mRNA expression values in uterus and ovary of TG-
LHR 3-months-old mice. The values were normalized on LHR expression of wt mice. A,B,D: 
Immunohistochemical analysis with anti c-myc antibody on representative samples of mouse 
uterus: c-myc is expressed in TG LHR- 200 (A), TG-LHR-100 (B), in C c-myc is absent (wt 
mouse). Magnification 20X. 
 
4.3 Morphologic and morphometric characterization 
For the histological characterization we sacrificed three 9-months old TG-LHR mice 
and the uterus were taken, formalin-included and paraffin-embeded (as in Material and 
Methods). 6µm-slides where stained with hematoxilin and eosin for  the histological 
analysis. The observation at the microscopy (1,6X magnification) shown an increase in 
the dimension of the uterus of the three TG mice compared to wild type animals. 
Moreover, it is worth noting that in 2 out of 3 of 9-months old transgenic animals is 
emerged an increase of the uterine cavity (LHR 108 e LHR 111) compared to wild type 
animal (wt 005) of the same age (Figure11A). 
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Figure 11: A: E/E staining was performed on uterus of 9-months old wt and TG-LHR mice. 
Magnification 1,6x. B,C: Representative samples of uterus showing Radius, ICM and LEH in 
13-months old wt mouse (B) and 12-months old TG-LHR (C) mouse. Magnification10X. 
 
For the subsequent assessment of the uterine morphometry of overexpressing LHR mice 
have been taken into account three parameters (GA Wood et all 2007): uterine radius, 
ICM (inner circular muscle) and LEH (luminal epithelium high) (Figure 11 B, C). It 
was observed an increase of the mean utrine radius in 6-12 months-old TG mice 
compared to wild-type mice (Figure 12); the same was observed for the thickness of the 
inner circular muscle (ICM). The luminal epithelial height (LEH) is similar in both wild 
type and TG-LHR mice. Moreover, transgenic and wt mice older than 12 months 
showed a similar radius thickness and LEH mean values. Instead, as concerning ICM, 
TG-LHR mice showed a mean thickness greater than wt animals (Figure 12). 
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Figure 12: Mean of the Radius, ICM and LEH values of both wt (white bars) and TG-LHR 
(grey bars) mice. All the mice are divided into to groups: 6-12 months-old, and more than 12 
months-old. 
 
4.4 Immunohistochemical Characterization 
Our next objective was to examine whether hLHR over-expression results in basement 
membrane alterations and myometrial invasion. Myometrial invasion is evalued 
investigating the presence of α-smooth-muscle actin (α-sma) because it is frequently 
express in myofibroblasts (Daikoku T. et al 2008). In all the samples it was evaluated 
the expression of α-sma by immunihistochemical analisys with anti-α-sma antibody (as 
described in Materials and Methods). 
In all the wild-type mice stained with α-sma (4 out of 4) the labeling was present only in 
the muscular cells (Figure 13A), while in TG-LHR mice samples (8 out of 8) the 
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labeling was present both in the muscolar cells and in the glandular epithelium, 
probably indicative of transdifferentiation (Figure 13B).  
We than performed Ki67 immunostaining in uterine sections of wild-type and TG-LHR 
mice in order to determine the proliferation status (Figure 13C and D).  
 
Figure 13: A,B: IHC was performed as described in Materials and Methods with anti α-sma 
antibody in wt mouse (A) and in TG-LHR mouse (B). Magnification 20X. C,D: IHC with anti 
Ki67 antibody. Negative sample for Ki67 staining (C) and positive sample for Ki67 staining 
(D). Magnification 20X. 
 
The evaluation of Ki67 protein expression was performed taking into account the 
percentage of labeled nuclei in three different areas: the luminal epithelium, stromal 
cells and the endometrial glandular cells. We observed higher percentage of Ki67-
positive cells in the stroma of 6-12 months-old transgenic mice compared to wild type 
animals, instead, a similar mean percentage of positive cells was observed between 
transgenic and wt mice older than 12 months. Moreover, Ki67 protein was found at 
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increased levels in the luminal epithelial cells of transgenic mice older than 12 months 
compared to wt mice of the same group of age (Table 2). 
 
Table 2: Mean percentage of positive cells to Ki67 staining in epithelial cells, glandular cells 
and stromal cells in both wt and TG mice. All the mice are divided into two groups of age: 6-12 
months old and more than 12 months old. 
 
All the animals sacrificed and used for morphometric and immunhistochemical 
characterization are reported and detailed in table 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age  WT TG 
 
6-12 months 
Epithelial cells 3% 
Glandular cells 1% 
Stromal cells 18% 
Epithelial cells 3% 
Glandular cells 5% 
Stromal cells 30% 
 
> 12 months 
Epithelial cells 3% 
Glandular cells 0% 
Stromal cells 20% 
Epithelial cells 8% 
Glandular cells 1% 
Stromal cells 20% 
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Table 3: Rapresentation of all the mice used for morphological and immunohistochemical 
analysis. For each sample we performed hematoxilin and eosin (H & E) and 
immunohistochemical staining with anti-c-myc, anti-KI67 and anti-α-SMA antibodies. 
MOUSE AGE 
(mounth) 
H & E  IHC  
C-MYC 
IHC KI 67 IHC α-SMA 
 
WT 5  
 
9 
 
X 
 
- 
Epithelial cells 0% 
Glandular cells 1% 
Stromal cells 30% 
 
 
+ in uterine myocytes 
 
WT 6  
 
13 
 
X 
 
- 
Epithelial cells 5% 
Glandular cells 0% 
Stromal cells 10% 
 
 
+ in uterine myocytes 
 
WT 8  
 
18 
 
X 
 
- 
Epithelial cells 5% 
Glandular cells 1% 
Stromal cells 30% 
 
 
+ in uterine myocytes 
 
TG LHR 
108  
 
9 
 
X 
 
+ 
Epithelial cells 0% 
Glandular cells 0% 
Stromal cells 20% 
 
 
+ in uterine myocytes and 
glandular epithelium 
 
TG LHR 
109  
 
9 
 
X 
 
+ 
Epithelial cells 0% 
Glandular cells 10% 
Stromal cells 40% 
 
 
+ in uterine myocytes and 
glandular epithelium 
 
TG LHR 
111 
 
9 
 
X 
 
+ 
Epithelial cells 0% 
Glandular cells 0% 
Stromal cells 30% 
 
 
+ in uterine myocytes and 
glandular epithelium 
 
TG LHR 
101  
 
12 
 
X 
 
+ 
Epithelial cells 0% 
Glandular cells 10% 
Stromal cells 30% 
 
 
+ in uterine myocytes and 
glandular epithelium 
 
TG LHR 
103  
 
12,5 
 
X 
 
+ 
Epithelial cells 10% 
Glandular cells 5% 
Stromal cells 40% 
 
 
+ in uterine myocytes and 
glandular epithelium 
TG LHR 
105  
 
17   
 
X 
 
+ 
 
+ in all the mass 
 
+ in all the mass 
 
TG LHR 
207  
 
 
13 
 
 
X 
 
 
       + 
Epithelial cells not evaluable 
Glandular cells 0% 
Stromal cells 20% 
 
 
+ in uterine myocytes and 
glandular epithelium 
 
TG LHR 
211  
 
16 
 
X 
 
+ 
      Epithelial cells 5% 
Glandular cells 0% 
Stromal cells 5% 
 
+ in uterine myocytes and 
glandular epithelium 
 
TG LHR 
123  
 
17 
 
X 
 
+ 
      50% mass cells; 
Epithelial cells 20% 
Glandular cells 0% 
Stromal cells 20% 
 
+ in uterine myocytes and 
glandular epithelium 
 
WT  
 
23 
 
X 
 
- 
Epithelial cells 0% 
Glandular cells 0% 
Stromal cells 20% 
 
 
+ in uterine myocytes 
 
WT 2 
 
7 
  Epithelial cells 5% 
Glandular cells 0% 
Stromal cells 5% 
 
 
 
TG LHR 
200 (6) 
 
9 
  
+ 
Epithelial cells 5% 
Glandular cells 0% 
Stromal cells 30% 
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4.5 Pathological findings in LHR-TG mice 
In two 17-months-old mice (TG-LHR 105 and TG-LHR 123) we found a mass at the 
uterus level. In TG-LHR 105 mouse a huge mass it was localized in the lower abdomen 
(Figure 14 A, B, C), while in TG-LHR 123 mouse a smaller-sized mass was in the 
lower-third of the left uterine horn (Figure 14 A,B). Both the masses were taken and 
formalin-fixed and paraffin-embedded for immunohistological analisys. The tissue of 
the large-sized mass of TG-LHR 105 mouse was completely transformed and it is 
unrecognizable the typical uterine architecture (Figure 14D).  
 
 
Figure 14: A: Macroscopic picture of TG-LHR 105 mouse, sacrificed at 17-months old. B: 
Tumor mass, indicates with the red arrow, at the moment of explant. C: Tumor mass. D: Mass 
stained with Ematoxilin and Eosin. Magnification 10x. 
 
The mass of TG-LHR 123 mouse was small-sized and the tissue lost the normal uterine 
architecture, although the inner circular muscle layer was still visible (Figure 15 C, ICM 
is indicated with red arrow). All the elements that characterize the uterine tissue (inner 
circular muscle, uterine cavity, luminal epithelium) are maintained in the other healthy 
horn (Figure 15 D). 
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Figure 15: A: Macroscopic picture of TG-LHR 123 mouse during the explant; the red arrows 
indicates the uterus. B: Uterus explanted with mass in the lower-third of the left  horn (blue 
arrow). C: Left horn with mass stained with E/E. Magnification 10x. D: Healthy right horn 
stained with E/E. Magnification 10x. 
 
 
 
.
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5. DISCUSSION 
 
Published data highlight that the interaction between luteinizing ormone (LH) and its 
receptor (LHR) plays a role in the progression of endometrial cancer, especially in the 
acquisition of a more invasive potential. The increased ability of EC cells to undergo 
local invasion and metastatic spread, promoted by the binding of LH to its receptor, was 
also demonstrated by our group in an orthotopic/menopausal mouse model (Pillozzi S et 
al 2013). In order to evaluate the effect of LHR over-expression and to assess if it could 
be capable per se of inducing the development of an EC, we produced a transgenic 
mouse model over-expressing LHR in female reproductive tracts. The real time PCR 
and the immunohistochemistry analysis confirmed the presence of the transgene in the 
uterus and ovary in both the two lines of transgenic mice (LHR-100 and LHR-200). 
Studying the expression of hLHR mRNA in TG-LHR mice it emerged that in uterus and 
liver the transgene is expressed at high levels and the different expression level between 
transgenic and wt animals it is statistically significant. The hepatic ectopic 
overexpression of the transgene it is probabilly due to the insertion site of the transgene 
or to epigenetic causes. Analysis to determine the transgene copy number inserted in 
transgenic animals are ongoing. Further analysis were performed to characterize the 
uterine morphometry taking into account the uterine radius, inner circular muscle (ICM) 
and luminal epithelial height (LEH). Radius and ICM were increased in 6-12 months-
old transgenic mice compared to wt animals of the same age, whereas no differences 
were observed in LEH. On the contrary, radius thickness and LEH showed a similar 
mean values in both transgenic and wild type mice older than 12 months. Instead, as 
concerning ICM, TG-LHR mice showed a mean thickness greater than wt animals. To 
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deepen this topic, we investigated cell proliferation evaluating Ki67 staining in 
epithelial, glandular and stromal cells of the uterine mucosa. From such analysis, it 
emerged that 6-12 months-old TG mice showed higher proliferation rate compared to 
wt mice, whereas in mice older than 12 months the proliferation rate was similar both in 
wt and TG mice. Moreover, old mice over-expressing LHR showed an increased 
proliferation rate in epithelial luminal cells compared to wt. We then examined whether 
LHR over-expression might affect basement membrane alterations and myometrial 
invasion by investigating the presence of α-smooth-muscle actin (α-sma) that is known 
to be frequently expressed in myofibroblasts (Daikoku T. et al 2008). Differences were 
observed between transgenic and wt mice of both age groups. In particular, α-sma was 
expressed only in muscular cells of wt mice, whereas in all TG mice it was expressed 
not only in the myocites but also in the glandular epithelium, probably indicating  
transdifferentiation. 
From the histological analysis it emerged that two 17-months old TG mice developed 
tumor masses. Interestingly, in LHR-105 TG mouse a huge masses occupying the entire 
abdomen was observed, while in TG LHR-123 the mass was localized in the lower-third 
of the left uterine horn. Although these results were observed in a small subset of 
animals, they are quite interesting since might suggest a potential causative role of LHR 
in endometrial cancer pathogenesis, besides its role in tumor invasion and metastatic 
potential (Pillozzi S et al 2013). Considering LHR ability to regulate PKA signaling 
(Dabizzi S et al 2003), such scenario could be related to the modulatory effects that 
LHR exerts on intracellular signaling pathways which control cell proliferation, survival 
and invasiveness. This topic deserves further attention and it is worth investigating in 
the future. Additional microarray analyses are ongoing to better investigate the pattern 
of genes involved in the developing of the two masses, to deepen this topic and better 
characterize LHR transgenic animals. 
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The effect of the over-expression of LHR will be further evaluate on the susceptibility 
to carcinogenic agents. The use of such model allowed us to conclude that TG LHR 
mice may represent a useful model for the study of endometrial cancer in vivo and in 
particular to assess therapeutic intervention and pharmacological tests. 
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CHAPTER 3 
 
 
In last years many data have been collected about the in vitro and in vivo role of 
luteinizing hormone receptor (LHR) that tend to configure the LH/LHR axis as a 
progression factor in EC, contributing to regulate cell invasion and angiogenesis, and hence 
ultimately leading to metastatic spread. In this part of the thesis we evaluated the 
expression levels of LHR gene in a case series of EC. In addition, we also evaluated in 
the case series the mRNA levels of two ion channels (hERG1 and KCNA7), known to 
be dysregulated in EC. 
 
1. INTRODUCTION 
 
1.1 EPIDEMIOLOGY OF ENDOMETRIAL CANCER 
Endometrial cancer (EC) is nowadays the most common gynecologic malignancy and 
the most frequent among infiltrating tumor of the female genital tract, the sixth most 
common cancer in women worldwide (fourteenth most common cancer overall), with 
319.000 new cases and 76.000 deaths per year (Ferlay J et al. 2012; Sartori E. et al 
2010; Matias-Guiu X. et al 2001). Approximately 75% of the cases are related to the 
corpus uteri and 15-20% of these have relapse and are unresponsive to systemic therapy 
(Amant F. et al. 2005). In the Europe about 99.000 new cases of EC and 23700 deaths 
were reported in 2012. Concerned Italy, it is at the eighteenth position in Europe whit 
8471 new cases with 1955 death every year (Ferlay J et al. 2012) (Figure1). 
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Figure 1: Bar chart representing the incidence and the mortality of EC in the 20 European 
countries with highest incidence of Endometrial Carcinoma (Globocan 2012). 
 
The analysis of EC incidence trends showed an increasing during „60s of the last 
century with a peak during the 70s and than a subsequent stabilization. The incident 
trend showed an increase in postmenopausal age and in particularly in industrialized 
countries, rather than in developing countries (Cook SL et al., 2006). There are distinct 
patterns in the age-specific trends of EC. A general profile emerged of increasing risk in 
postmenopausal women (ages >55 years), and decreasing or stable trends in 
premenopausal and perimenopausal women (ages 30-54 years), particularly in Northern 
and Western countries. The most consistent declines in these regions were observed in 
women ages 45 to 54 years (Bray F. et al., 2005). The incidence of EC among white 
women it is higher compared with African-American women, while five-year survival 
was poorer for African-American women, even for patients with the more favorable 
Stage I adenocarcinoma who were treated surgically (Hicks ML et al 1998). In Tuscany 
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the risk for a woman (from 0 to 84 years) to develope EC is about 2% (1 in 50 women), 
whereas the mortality rate is approximately 0,1% (1 in 736 women). 
 
1.2 CLASSIFICATION 
1.2.1 FIGO classification 
The first classification of Endometrial Cancer was formulated by F.I.G.O (International 
Federation of Gynecology and Obstetrics) in 1971 and consists in classification of EC in 
stages, based on clinical data, analysis of endometrial biopsy or measurement of the 
uterine cavity. This classification has three stages of EC: Stage 0 includes in situ 
carcinomas, Stage I includes tumors confined to corpus uteri, Stage II includes tumors 
that invades cervix. This first classification was incomplete because do not consider 
pathological parameters such as histological grading, myometrial infiltration, peritoneal 
histology and lymph nodal diffusion. In 1988 it was introduced by F.I.G.O. a new 
classification based on pathological factors. A revised version was introduced in 2009, 
with a rationale to further improve the prognostic performance of surgical staging. Main 
changes for the FIGO 2009 system include: noninvasive tumors and tumors with <50% 
myometrial invasion are combined; cervical glandular involvement does not affect 
staging; peritoneal cytology does not affect staging; tumors with lymph node metastasis 
are subdivided to stages IIIC1  and IIIC2 (Table 1) (Haltia UM et al 2014; Amant F et al 
2012). 
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Table 1: Stages of endometrial carcinoma (Amant F et al 2012). 
 
Another classification use the TNM staging system, in which are taken into account 
three parameters: the size of the primary tumor (T); regional lymph nodes involvement 
(N); presence of distant matastasis. Comparison of the F.I.G.O. with the TNM 
classification is given in Table 2. 
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Table 2: Endometrial carcinoma: FIGO staging compared with the TNM classification (Amant 
F et al 2012). 
 
1.2.2 Grading 
Furthermore for each stage it is important to associate a Grading system, which 
represent the differentiation rate of the tumor. 
 G1: Well differentiated (Low grade) 
 G2: Moderately differentiated (Intermediate grade) 
 G3: Poorly differentiated (High grade) 
Cases of EC should be grouped with regard to the degree of differentiation of the 
adenocarcinoma as follows:  
• G1: <5% of a nonsquamous or nonmorular solid growth pattern 
• G2: 6%-50% of a nonsquamous or nonmorular solid growth pattern 
• G3: >50% of a nonsquamous or nonmorular solid growth pattern 
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1.2.3 Histopathologic Classification 
Two major types of EC are distinguished on the bases of histological features: 
Type I: commonly referred to as the endometrioid type it is estrogen-dependent and 
develops through the hyperplasia-carcinoma sequence. These tumors comprises 80% of 
all endometrial cancers and arises in relatively younger pre- and post-menopausal 
women. They usually are low grade with an endometrioid morphology, and they are 
characterized by a favorable prognosis. Histologically, these tumors can be 
adenocarcinoma with or without squamous differentiation and often are well 
differentiated. Furthermore, epidemiological evidence suggests that the multistep 
carcinogenic process of Type I endometrial tumors begins with simple endometrial 
hyperplasia, progresses to complex atypia hyperplasia, and then develops into the 
precursor lesion, endometrial intraepithelial neoplasia (EIN) (Felix AS et al 2010). 
Type II: Type II EC, or non-endometrioid tumors, encompasses the remaining 10–20% 
of sporadic endometrial tumors.  The two histologies of this subtype are uterine 
papillary serous carcinoma and clear-cell carcinoma (Felix AS et al 2010). These 
tumors arises in relatively older women and are not usually preceded by a history of 
unopposed estrogen exposure, but rather from a background of atrophic endometrium. 
Type II tumors have an aggressive clinical course, a greater propensity for early 
spreading, and a worse prognosis than the more common endometrioid 
adenocarcinomas (Doll A et al 2008). While the incidence of Type II tumors is low 
compared to Type I, excess mortality is associated with Type II. The main features of 
Type I and Type II EC are summarized in Table 3. 
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Table 3: Clinico-pathological characteristics and genetic abnormalities in Type 1 and Type 2 
endometrial carcinomas (Ryan AJ et al 2005).    
 
The prognostic value of these two main subgroups are limited because it does not 
explain the causes of 20%  recurrences in the Type I EC and 50%  recurrences in Type 
II EC (Rose PG, 1996). 
 
1.3 RISK FACTORS FOR EC DEVELOPMENT 
Although the etiology is not completely clear, the endometrial carcinoma is associated 
with many risk factors: 
Obesity: large body mass in general, and obesity in particular, has been linked to an 
increased risk of endometrial cancer in many studies. Some studies also suggest that the 
association between large body mass and endometrial cancer is stronger or more 
consistent in post-menopausal women (Tornberg SA et al 1994). An association with 
obesity is biologically plausible. Post-menopausal obese women are known to have 
higher endogenous oestrogens than lean women65 due to the aromatization of 
androstenedione in adipose tissue (Austin H et al 1991;  Purdie DM 2001). 
Estrogens: The predominant theory describing the relationship between endogenous 
steroid hormones and endometrial cancer risk is known as the unopposed estrogen 
hypothesis. This hypothesis proposes that endometrial cancer risk is increased in 
women who have high plasma bioavailable estrogens and/or low plasma progesterone, 
so that mitogenic effects of estrogens are insufficiently counterbalanced by progesterone 
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(Key TJ et al 1998).  This theory originated from at least two important observations: 
(a) increased endometrial proliferation rates during the follicular phase of the menstrual 
cycle, during which progestin levels are low, whereas E2 levels are at normal 
premenopausal concentrations; (b) increased endometrial cancer risk among women 
using exogenous estrogens without progestins (Hormonal contraception and 
postmenopausal hormonal therapy, 1999; Kaaks R et al 2002). The use of the combined 
oral contraceptive pill (estrogen plus progestogen) reduces the risk of endometrial 
cancer has been reported consistently and the protective effect of the combined oral 
contraceptive pill does not depend on the dose of the progestogen (Parslov M et al 2000; 
Purdie DM 2001; Weiderpass E et al 1999 ). Long-term use of combined oral 
contraceptives seems to reduce the risk further, and the protective effect lasts for 20 or 
more years after discontinuation (Weiderpass E et al 1999). 
Tamoxifen therapy: tamoxifen has an anti-estrogenic effect and is often used as 
adjuvant therapy for women with breast cancer. Results from clinical trials in women 
with breast cancer have highlighted a potential increase in endometrial cancer resulting 
from use of these anti-estrogens (Mignotte H et al 1998). The risk has also been seen to 
increase with increasing duration of treatment with tamoxifen and increasing cumulative 
dose.  
Nulliparity/infertility: nulliparity could be a manifestation of infertility, which, in turn, 
has been separately identified as a risk factor for endometrial cancer. Infertility is 
difficult to measure retrospectively with accuracy, however, and therefore the risk 
associated with it is difficult to quantify. Numerous surrogate measures have been used, 
for example, married nulliparous women have been found to be at greater risk than 
unmarried nulliparous women (Parazzini F et al 1991). 
Diabetes: Diabetes mellitus is another condition long known to be associated with 
endometrial cancer (Weiderpass E et al 2000; Elwood JM et al 1997). One possible 
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explanation is that these conditions are simply markers of obesity. It has  been 
suggested that the increased risk associated with diabetes may be restricted to obese or 
overweight women (Weiderpass E et al 2000). 
 
1.4 MOLECOLAR BIOLOGY OF EC 
EC is characterized by a variety of genetic alterations, the most frequent of which is to 
the PTEN gene. The genes code for proteins inhibiting tumor growth. PTEN encodes a 
protein (phosphatase and tensin homolog, PTEN) with tyrosine kinase function and 
behaves as a tumor suppressor gene. PTEN has been reported to be altered in up to 83% 
of endometrioid carcinomas and 55% of precancerous lesions (Mutter GL 2001). PTEN 
inactivation is caused by mutations that lead to a loss of expression and, to a lesser 
extent, by a loss of heterozygosity. Loss or altered PTEN expression results in aberrant 
cell growth and apoptotic escape. Loss of PTEN is furthermore probably an early event 
in endometrial tumorigenesis. Its expression is highest in an estrogen-rich environment; 
in contrast, progesterone promotes involution of PTEN-mutated endometrial cells (Kim 
YB et al 1997; Tsikouras P et al 2013).  
Mutations in PIK3CA may contribute to the alteration of the phosphatidylinositol 3 
kinase (PI3K)/AKT signaling pathway in EC (Yeramian A et al 2012). A high 
frequency of mutations in the PIK3CA gene has been reported in EC. PIK3CA 
mutations occur in 24–39% of the cases, and frequently coexist with PTEN mutations. 
PIK3CA mutations have been associated with adverse prognostic factors such as high-
grade and myometrial invasion (Oda K et al 2005). The most common genetic alteration 
in type 2 serous carcinomas is in p53, the tumor suppressor gene. Mutations in p53 are 
present in about 90% of serous carcinomas (Lax S et al 2004).  The exact mechanism 
behind the cause of this mutation is still unclear but it is postulated that mutation in one 
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allele occurs early during the development of serous carcinoma, and loss of the second 
normal allele occurs late in the progression to carcinoma. Other genetic alterations in 
endometrioid EC include microsatellite instability (MSI) and specific mutations of K-
ras and β-catenin genes. MSI and K-ras mutations have been reported in about 20% of 
endometrioid cancer (Kandoth C et al 2013; Yeramian A et al 2012).  Frequent genetic 
alterations in type 2 ECs are inactivation of p16 and overexpression of HER-2/neu 
(Konecny GE et al 2009). P16 inactivation was found in 45% of serous carcinomas and 
some clear cell cancers. The p16 tumor suppressor gene is located on chromosome 9p21 
and encodes for a cell cycle regulatory protein. Inactivation of p16 leads to uncontrolled 
cell growth. HER-2/neu overexpression has been associated with a metastatic phenotype 
and poor survival in type 2 EC (Konecny GE et al 2009).  
The recent mapping of the genomic landscape of serous and endometrioid endometrial 
carcinomas has resulted in the first comprehensive molecular classification of these 
tumors and has distinguished four molecular subgroups: a POLE/ultramutated 
subgroup, a hypermutated/microsatellite unstable subgroup, a copy number 
low/microsatellite stable subgroup, and a copy number high subgroup. This molecular 
classification may ultimately serve to refine the diagnosis and treatment of women with 
endometrioid and serous endometrial tumors (Le Gallo M et al 2015). 
 
1.5 LHR AND ENDOMETRIAL CANCER 
Endometrial cancer occurs most commonly in postmenopausal women and is therefore 
coincidentally associated with elevated plasma LH levels (Nagamani et al, 1993). 
Studies strongly suggest that high postmenopausal levels of LH are stimulating 
endometrial cancer cell growth but not via the classical LH receptor-cAMP pathway 
(Davies S et al, 2000). LH receptor gene expresses in endometrium normal tissue at 
very low levels, while an increased expressions of LHR has been found in endometrial 
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cancerous tissues (Ji Q et al, 2002). The activation of LHR in endometrial cancer cells is 
established that promotes cancer local invasion metastatic progression and the capability 
of invading in response to LH addition was dependent on PKA activation (Dabizzi S et 
al, 2003; Noci I et al 2008)  The mechanism for this involves LH binding to its receptor 
and inducing the activation of PKA, which in turn induces a functional activation of 
beta 1 integrin receptors and the subsequent secretion of active matrix 
metalloproteinase-2 ending in the triggering of cell invasiveness (Dabizzi S et al, 
2003). The increased ability of EC cells to undergo local invasion and metastatic spread, 
promoted by the binding of LH to its receptor, was also demonstrated by our group in 
an orthotopic/menopausal mouse model (Pillozzi S et al 2013). The model consisted in 
an orthotopic xenograft of Hec1A cells into immunodeficient mice treated with 
recombinant LH, to assure high levels of LH. In particular, it was observed that tumors 
arising from Hec1A-LHR cells injection displayed a higher local invasion and a higher 
number of distant metastases, mainly in the lung, compared to tumors obtained from the 
injection of Hec1A cells. LH withdrawal strongly inhibited local and distant metastatic 
spread of tumors, especially those arising from Hec1A-LHR cells (Pillozzi S et al 
2013). In a recent paper have been described high levels of expression of LHR at both 
mRNA and protein levels in a patient with EC who experienced early relapses, even 
though she was defined as low risk according to the current guidelines. For this reason it 
may be possible to sustain that there is a relationship between high LHR expression and 
biological aggressiveness of EC (Noci et al, 2016). 
 
1.6 hERG1 CHANNEL AND ENDOMETRIAL CANCER 
EC is a heterogeneous disease and novel biomarkers are urgently needed in order to 
better stratifying EC patients and ensuring the best treatment options. The first paper 
demonstrating the expression of hERG1 potassium channels in human primary cancers 
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was conducted on EC samples (Cherubini A et al 2000). In such paper it was 
demonstrated that hERG1 mRNA can be detected in human tissues by end-point RT-
PCR as well as by immunihistochemestry and is more frequently expressed in human 
neoplastic tissues compared to normal endometrium and hyperplastic lesions (Cherubini 
A et al 2000). Furthermore, patch clamp analysis indicated that functional hERG1 
proteins are expressed on the cell surface of EC cells. This paper opened the way for 
further investigation of hERG1 expression in clinical samples, although the analysis 
was carried out on a small group of EC patients. 
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2. MATERIALS AND METHODS 
 
 
2.1 Description of the prospective cohort 
 
For this study, we enrolled a cohort of 123 patients with pathologically confirmed 
endometrial cancer treated at the AOUC Careggi Hospital from 19 march 2013. 
Samples were collected after obtaining an informed written consent from all the patients 
at the moment of surgery in RNA later (Sigma-Aldrich), in order to preserve RNA 
integrity. After the collection the tumor samples were conserved at -80°C. The 
treatment protocol was developed according to ITT (Istituto Toscano Tumori) 
guidelines and international guidelines. A database has been created in order to collect 
the clinical and pathological parameters such as tumor histotype, grade of 
differentiation, FIGO stage, myometrial invasion, presence or absence of menstruation. 
Not all clinical pathological parameters were available for all patients involved in this 
study. Patients are ranged from 39 to 92 years, with a median age of 65 years. Post-
menopausal women were hundred and twelve (89%) at the moment of the surgery. 
EC patients enrolled in the study were divided in two subgroups based on histological 
type. Hundred and eleven (90%) patients had an endometrioid tumor histotype, whereas 
twelve (10%) patient had a non-endometrioid histotype (Figure 7). 
 
Chapter 3 
 
89 
 
Materials and Methods 
 
 
 
The case series was also divided according to the FIGO classification. One hundred-
three patients (86%) belong to the Stage I (Ia and Ib), seven (6%) belong to the Stage II 
and nine (8%) to the Stage III ( IIIa, IIIb and IIIc) (Figure 8). 
 
 
 
Among 123 patients, the most represented histological grade was the G2, with fiftyeight 
patients (47%). In thirtyfive patients (29%) the tumor was poorly differentiated (G1), 
whereas in thirty patients (24%) the tumor was well differentiated (G3) (Figure 9). 
Figure 7: Percentage of patients belonging to Endometrioid and Non endometrioid. 
histotype 
 
 
Figure 8: Distribuition of patients based on FIGO staging. 
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Traditionally, the percentage of myometrial invasion, categorized as <50% or >50%, is 
one of the parameters used in the determination of the need for adjuvant radiotherapy. 
In sixty-eight (59%) cases of EC patients the infiltration was less than 1/2 myometrial 
depth, whereas in forty-eight (41%) it was greater than 1/2 myometrial depth (Figure 
10). 
 
 
 
 
Figure 9: Patients distribution based on histological grade. 
Figure 10: Patients distribution on the basis of myometrial infiltration: <50% 
myometrial infiltration vs >50% myometrial infiltration. 
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All the patients enrolled in this study were divided in two groups based on clinical and 
pathological parameters:  
 Low-Risk EC subgroup: Endometrioid EC, G1 or G2 grading, <50% myometrial 
invasion (Stage Ia). 
 High-Risk EC subgroup: Endometrioid EC+G3 grading and/or >50% 
myometrial invasion (Stage ≥ Ib). Non endometrioid EC. 
Sixty-nine patients (55%) belong to Low-Risk subgroup, whereas fifty-seven (45%) 
patients belong to High-Risk subgroup (Figure 11). 
 
 
 
 
2.2 RNA estraction and reverse transcription  
Fresh endometrial cancer specimens and were dipped in TRIzol Reagent (Invitrogen) 
and homogenized to isolate total RNA according to manufactorer‟s protocol. The cDNA 
was synthesized from 1 µg of total RNA using 200U/µL of SuperScript II Reverse 
Transcriptase (Invitrogen), adding for each sample 500 µmol/L of deoxyribonucleotide 
triphosphate (dNTP) (Invitrogen) and 15 ng/µL of random primers (Invitrogen).  
Figure 11: On the bases of histological type, histologic grade and myometrial invasion, 
patients are divided in two bubgroups: Low-risk and High-risk. 
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The reaction starts preparing a mix with: 
 1µg of RNA 
 2 μl of Random Primers (diluited 1:20 from the stock solution) 
 1 µl of dNTPs (10mM) 
 ddH₂O till a final volume of 12 µl 
The mix was incubated in a thermal cycler at 65°C for five minutes, and then 
immediately placed on ice for five minute. Then, 4 µl of Buffer 5X First Strand 
(Invitrogen) and 3 µl of ddH₂O were added to the tube. The mix was heated at 25 °C for 
2 min and than added with the SuperScript II. The mix was than incubated as follows: a 
first step at 25°C for 10 min followed by 50 min at 42°C and a final step at 70°C for 15 
min. 
 
2.3 Real Time PCR 
hLHR, KCNH2 and KCNA7 expression levels were evaluated by real-time 
quantitative PCR (qPCR) using 1µL of cDNA. The expression levels of genes were 
normalised to the levels of GAPDH housekeeping gene. SYBR green fluorescent dye 
were used to monitor the DNA synthesis. The primers pairs for LHR, KCNH2, 
KCNA7 and GAPDH were designed to spanning intron/exon boundaries. All the 
Primers used for the clinical study are listed in table 4. 
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Table 4: Primers sequences 
 
All the primers were used at final concentration of 300 nM. PCR program start with an 
incubation at 95 °C for 10 min, followed by 40 cycles of amplification: denaturation at 
95 °C for 15 s and annealing–extension step at 60 °C for 1 min. The relative 
quantification of hERG1 expression levels was performed by the ΔCt method. Each 
reaction was performed in triplicate. Melting curve analysis of the amplicons were 
performed to exclude the amplification of a specific products or primer-dimer artefacts. 
Relative expression values of LHR and KCNA7 were normalized for the expression 
value of Hec1A cells (low expression cell line). Expression values of KCNA7 gene was 
normalized for the expression value of  MDA-MB cells (low expression cell line). 
 
2.4 Statistical analysis 
 
For the statistical analysis clinical-pathological paramethers were categorized as 
fallows: age at the diagnosis; histology= endometrioid vs non endometrioid; 
differentiation grade= low, medium, high; FIGO= I, II, III and IV; risk= low vs high; 
myometrial invasion= less than 50% vs greater than 50%; postmenopause; body mass 
index (BMI). The associations between the values of expression LHR, KCNH2 and 
GAPDH L 
GAPDH R 
LH/R 2/3 UP 
LH/R 2/3 DN 
KCNA7_AL 
KCNA7_AR 
KCNH2-AF1-L 
KCNH2-AF1-R 
5‟ GCTCTCGCTCCTCCTGTT 3‟ 
5‟ ACGACCAAATCCGTTGACTC 3‟ 
5‟ TGCCTACCTCCCTGTCAAAG 3‟ 
5‟ TTGAGGAGGTTGTCAAAGG 3‟  
5‟ CTTCAATGACCCGTTCTTCGT 3‟ 
5‟ AAGTAGGGAAGGATAGCCACAA 3‟ 
5‟ ACGTCTCTCCCAACACCAAC 3‟ 
5‟ GAGTACAGCCGCTGGATGAT 3‟ 
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KCNA7 and clinical-pathological parameters were assessed applying the Spearman 
correlation test. P<0,05 was considered statistically significant. For the follow-up 
analysis the event free survival time (EFS) of patients was defined as the interval 
between the intervention and the relapse of the desease. Univariate analyses of event 
free survival time were calculated according to the Kaplan-Meier method. Comparisons 
between survival curves were performed using the long-rank test. For the EFS analysis 
LHR, KCNH2 and KCNA7 genes were categorized as 0/1 respect to their level of 
expression, lesser or greater than the median value. The statistical analysis were 
performed in collaboration of Dott. L. Tofani (University of Florence). 
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3. AIMS OF THE STUDY 
 
 
The aims of the present study was to assess the expression levels of a gonadotropin 
receptor, such as LH receptor, and two K
+
 ion channels (hERG1 and KCNA7) in a 
prospective cohort of primary EC samples provided by Azienda Ospedaliero-
Universitaria, Careggi, Florence. Furthermore we designed the present study in order to 
assess and validate the correlation between the expression levels of the three genes and 
clinical-pathological data and among the expression. The final goal will be to unravel 
the predictive value of LHR, KCNH2 and KCNA7 expressions levels to better stratify 
EC patients. 
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4. RESULTS 
 
 
 
Endometrial cancer is a heterogeneous disease and novel biomarkers are urgently 
needed. This will allow better stratifying EC patients and ensuring the best treatment 
options. In recent years it was studied the role of LHR in endometrial carcinoma. In 
particular it seems to promote local invasion and metastatic spread (Pillozzi S et al 
2013). Ion channels are involved in tumor progression in many types of cancer, in 
particular KCNH2 was demonstrated to be over-expressed in endometrial cancer 
(Cherubini A et al 2000). Moreover, preliminary data coming from a microarray 
analysis identified a number of ion channels with an expression profiles that may 
suggest their involvement in EC. We focused on LHR, KCNH2 and  KCNA7 
(potassium voltage-gated channel, shaker-related subfamily, member 7) genes because 
they seem to be the most dysregulated genes.  
 
4.1 Evaluation of expression levels of LHR, KCNH2 and KCNA7  
We evaluated the gene expression levels of LHR, KCNH2 and KCN7 in endometrial 
cancer by real time PCR. LH receptor expression level was analyzed on all the 123 EC 
samples collected at the AOUC Careggi Hospital, Florence. The GAPDH housekeeping 
gene was amplified as a control (as descrive in Materials and Methods). Overall, we 
found a strong variability in LHR expression level in the specimens analyzed, with a 
range between 0,26 and 5722973, and a median value of 73,78 (Figure 12). 
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The EC patients were evaluated also for the expression of KCNH2 and KCNA7 genes, 
because these ion channels are known to be dysregulated in several types of tumors. 
KCNH2 expression level ranged from 0,09 to 70077, with a median value of 76,11 
(Figure 13). 
 
 
 
 
 
 
 
Figure 12: Distribution of LHR mRNA expression values. The black line 
represent the median. 
Figure 13: Distribution of KCNH2 mRNA expression values. The black line 
represent the median. 
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Real time PCR analysis showed that KCNA7 expression was extremely heterogeneous 
in the cohort of patients, with a range between 0,01 and 4555 and a median value of 0,7 
(Figure 14). 
 
  
 
 
 
 
4.2 Statistical analysis 
 
LHR, KCNH2 and KCNA7 expression values were used to perform statistical analysis 
applying the Spearman Correlation Test (table 5). We observed that the expression of 
LHR is statistically associated with KCNH2 (p=0,0064) and KCNA7 (p<0,001). 
Furthermore, the expression of KCNH2 with KCNA7 is statistically associated 
(p<0,001). 
 
 
 
 
 
Figure 14: Distribution of KCNH2 mRNA expression values. The black line 
represent the median. 
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 Spearman index P value 
LHR/KCNH2 0,245 0,0064 
LHR/KCNA7 0,435 <0,0001 
KCNH2/KCNA7 0,561 <0,0001 
 
Table 5: Table representing the associations between LHR, KCNH2 and KCNA7 gene 
expression calculated with Spearman method and P values associated to the Spearman index. 
 
We than evaluated whether the expression of LHR, KCNH2 and KCNA7 were 
associated with clinical-pathological parameters. Statistically significant correlations 
were found between LHR mRNA high expession and low risk endometrial cancer (p= 
0,025) and between LHR overexpression and infiltration less than 50% myometrial 
depth. Statistically significant associations were found also between KCNH2 high 
expression and low FIGO stages (p= 0,01), low risk endometrial cancer (p= 0,019) and 
infiltration less than 50% myometrial depth (p= 0,036). Moreover, KCNA7 
overexpression was statistically associated with low risk endometrial cancer (p= 0,018), 
invasion less than 50% myometrial depth (p= 0,018) and postmenopause (p= 0,048) 
(table 6). 
 
  
FIGO 
 
 
Age at the diagnosis 
 
Histotype 
 
 
Risk 
 
 Sp. index P value Sp. index P value Sp. index P value Sp. index P value 
LHR 0,046 0,61 0,012 0,89 0,049 0,59 -0,20 0,025 
KCNH2 -0,228 0,01 0,015 0,87 0,15 0,095 -0,213 0,019 
KCNA7 -0,140 0,12 0,044 0,63 0,14 0,118 -0,214 0,018 
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Grading 
 
>50% myometrial 
invasion 
 
 
Postmenopause  
 
BMI 
 
 Sp. index P value Sp. index P value Sp. index P value Sp. index P value 
LHR -0,158 0,082 -0,224 0,014 0,087 0,341 0,146 0,113 
KCNH2 -0,172 0,057 -0,192 0,036 0,175 0,053 0,116 0,206 
KCNA7 -0,091 0,317 -0,126 0,018 0,179 0,048 0,072 0,435 
 
Table 6: Table representing the associations between LHR, KCNH2 and KCNA7 gene 
expression and clinical-pathological paramethers, calculated with Spearman method. P values 
associated to the Spearman index (Sp. index). 
 
 
Subsequently, analyzing the follow-up data, it emerged that ten patients belonging to 
the case series developed recurrence. Univariate analysis showed a relationship between 
patient relapse free survival time and the LHR gene expression. Overall, LHR low-
expression shows a trend of increased probability of patients recurrence (Kaplan-Meier, 
Long-rank test, p=0.17). Low-expression and high-expression were assigned on the 
bases of a threshold of 73,78, that rapresent the median of LHR expression values.  
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Figure 15: Kaplan-Meier curve of event free survival time (EFS): LHR low-expression shows a 
trend of increased probability of patients relapse not statistically significant. Long-rank test, 
p=0.17. LHR expression greater than the median=1; LHR expression lesser than the median=0. 
 
We than studied in detail the patients which developed recurrences, it emerged that four 
out of ten relapsed cases belong to low risk EC. LHR is expressed at high levels (greater 
than the median value) in two out of four low risk EC patient, while one out of four is 
expressed slightly below to the median threshold value (table 7). We can notice that two 
samples (Fi-67 and Fi-156) relapsed earlier than other cases, despite they belong to low 
risk group. In these two cases LHR expression value is far higher than the median LHR 
value. Moreover, the patient who developed the relapse earlier (Fi-156), showed an 
expression of LHR, KCNH2 and KCNA7 genes higher than the median values of each 
one of the three genes. 
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Samples Relapse free 
survival time 
LHR KCNH2 KCNA7 Risk Stage Myometrial 
invasion 
Fi-2 22 months 1 0 0 high I >50% 
Fi-10 17 months 0 0 0 high II >50% 
Fi-23 21 months 0 1 1 high I >50% 
Fi-27 14 months 0 0 0 high I >50% 
Fi-58 11 months 0 0 0 high I >50% 
Fi-67 9 months 1 0 1 low I <50% 
Fi-78 21 months 0 1 0 low I <50% 
Fi-85 13 months 0 1 1 high I >50% 
Fi-88 17 months 0 0 1 low I <50% 
Fi-156 6 months 1 1 1 low I <50% 
 
Table 7: table resuming the ten relapsed cases belonging to prospective case series. LHR, 
KCNH2 and KCNA7 expression values are divided into two groups: 1= the expression value is 
higher than the median, 0= the expression value is less than the median value. 
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5. DISCUSSION 
 
 
 
Endometrial cancer (EC) is nowadays the most common gynecologic malignancy and 
the most frequent among infiltrating tumor of the female genital tract. The incidence  is 
rising and five-year survival is worse today than in the past. Although our 
understanding of the pathophysiology of EC has improved, the results of potential 
therapeutic options, especially non-surgical treatments, have been disappointing. 
According to histopathological criteria, EC can been divided into two major types: type 
I and type II. Type I cancers, which account for 80-90% of sporadic tumors, are usually 
estrogendependent endometrioid adenocarcinomas and are preceded by endometrial 
hyperplasia. Conversely, type II tumors are a heterogeneous, poorly differentiated group 
of tumors, usually have late presentation, more aggressive behavior, and are 
characterized bypoor outcome. However, there are women with estrogen-dependent, 
well-differentiated type I EC relapsing earlier than expected and 1 out of 3 women 
dying of EC is thought to have early-stage locoregional disease at diagnosis (Jemal A et 
al 2004; Amant F et al 2005). Our abilities to identify patients at increased risk of 
relapse or patients more likely to better respond to therapy, are suboptimal. Deciphering 
the key factors/pathways responsible for the aggressiveness of cancers is mandatory, in 
order to better stratify EC patients and ensuring the best treatment options. In recent 
years it was established that LHR is positively involved in EC local invasion and 
metastatic spread (Pillozzi S et al 2013). In order to identify additional biomarkers that 
could integrate LHR expression data analysis, we focused on ion channel genes because 
the proteins encoded by such genes are involved in tumor progression of several 
different types of cancer. In particular, KCNH2 (hERG1) potassium channel was 
Chapter 3 
 
102 
 
Discussion 
described to be up regulated in endometrial cancer (Cherubini, 2000). Thus, a whole-
genome expression analysis was previously conducted and we identified a number of 
ion channels, including KCNH2, whose expression profiles may suggest their 
involvement in endometrial cancer (Fortunato A PhD thesis). Among these genes we 
focused on KCNH2 and KCNA7 genes because they seem to be the most dysregulated 
ion channel genes. For this reason we investigated the LHR, KCNH2 and KCNA7 
expression in a prospective cohort of 123 primary EC samples provided by Azienda 
Ospedaliero-Universitaria, Careggi, Florence. The distributions of LHR, KCNH2 and 
KCNA7 expression values showed a similar trend for these three genes, however, 
median expression values are different. Statistical analysis showed significant 
correlations between the expression level of each one of the three genes. Then, we 
investigated whether LHR, KCNH2, KCNA7 and clinical-pathological parameters are 
associated. Significant correlations were found between the high expression of LHR, 
KCNH2 and KCNA7 and low-risk EC subgroup and between the high expression of the 
three genes and invasion less than 50% myometrial depth. Moreover, high KCNA7 
expression is statistically correlated with postmenopause, while KCNH2 is associated 
with FIGO stage, so that samples belonging to low FIGO stages show a higher KCNH2 
median expression values. Subsequently, we analyzed the follow-up data and it emerged 
that ten patients developed recurrence. The majority of the relapsed cases belong to high 
risk EC, with an infiltration level greater than 50% myometrial depth, on the contrary 
four out of ten relapsed patients belong to low risk EC, stage I and an infiltration level 
lesser than 50% myometrial depth. We observed that the two cases with the shorter time 
of relapse belonged to the low risk subgroup and showed a high level of LHR and 
KCNA7 expression. One of these two cases, which had 6 months of recurrence-time, 
showed also a high level of KCNH2 expression. Taken together, this data may suggest 
that these three genes, in particular LHR, may have a role in recurrence-time and in the 
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developing of a more aggressive phenotype that is not in agreement with type I 
histopatological classification. In other words, LHR, KCNH2 and KCNA7 could 
identify patients with low-risk EC characterized by higher probability to relapse.  
The study reported in this PhD thesis, is prospective one, therefore the follow-up time is 
different among patients and the small number of relapse is probably due to the short 
follow-up period. For these reasons the results are still preliminary and not conclusive 
and it will be necessary to complete the study analyzing a bigger cohort of patients for a 
longer period thus expanding both the number of patients enrolled and the follow-up 
time. Overall, in the field of endometrial cancer these three genes could contribute to 
better stratify EC patients belonging to the low-risk subgroup. 
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